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ABSTRACT  
   
The need for a renewable and sustainable light-driven energy source is the 
motivation for this work, which utilizes a challenging, yet practical and attainable 
bio-inspired approach to develop an artificial oxygen evolving complex, which 
builds upon the principles of the natural water splitting mechanism in oxygenic 
photosynthesis. In this work, a stable framework consisting of a three-dimensional 
DNA tetrahedron has been used for the design of a bio-mimic of the Oxygen-
Evolving Complex (OEC) found in natural Photosystem II (PSII). PSII is a large 
protein complex that evolves all the oxygen in the atmosphere, but it cannot be 
used directly in artificial systems, as the light reactions lead to damage of one of 
Photosystem II's core proteins, D1, which has to be replaced every half hour in 
the presence of sunlight. The final goal of the project aims to build the catalytic 
center of the OEC, including the Mn4CaCl metal cluster and its protein 
environment in the stable DNA framework of a tetrahedron, which can 
subsequently be connected to a photo-stable artificial reaction center that 
performs light-induced charge separation. Regions of the peptide sequences 
containing Mn4CaCl ligation sites are implemented in the design of the aOEC 
(artificial oxygen-evolving complex) and are attached to sites within the 
tetrahedron to facilitate assembly. Crystals of the tetrahedron have been obtained, 
and X-ray crystallography has been used for characterization. As a proof of 
concept, metal-binding peptides have been coupled to the DNA tetrahedron which 
allowed metal-containing porphyrins, specifically Fe(III) meso-Tetra(4-
sulfonatophenyl) porphyrin chloride, to be encapsulated inside the DNA-
  ii 
tetrahedron. The porphyrins were successfully assembled inside the tetrahedron 
through coordination of two terminal histidines from the orthogonally oriented 
peptides covalently attached to the DNA. The assembly has been characterized 
using Electron Paramagnetic Resonance (EPR), optical spectroscopy, Dynamic 
Light Scattering (DLS), and x-ray crystallography. The results reveal that the spin 
state of the metal, iron (III), switches during assembly from the high-spin state to 
low-spin state. 
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1. INTRODUCTION 
1.1 Oxygenic Photosynthesis 
Photosynthesis is one of the most fascinating and important processes on 
Earth, as it enables light energy to be converted into chemical energy to provide 
organisms with necessary food and energy. The general reaction of 
photosynthesis is shown below. 
6CO2 + 6H2O   C6H12O6 + 6O2  (in the presence of light) 
It is this pathway that paved the way for an oxygenic atmosphere for all higher 
life on Earth including humans to exist. In photosynthetic organisms, the electron 
transport chain consists of three large multimeric membrane complexes that are 
key components in generating chemical energy from solar energy. Oxygenic 
photosynthesis occurs in the thylakoid membranes of photosynthetic organisms.  
Excitation energy transfer begins with the absorption of a photon by the 
peripheral antenna systems surrounding PSII and PSI. From there, excitation 
energy is transferred to P680 and P700, the primary donors in PSII and PSI which 
results in an excited state, leading to a charge separation event in the reaction 
centers [1,2]. The electrons for the electron transfer reactions come from the 
oxidation of 2H2O to dioxygen, four protons, and four electrons catalyzed by the 
oxygen-evolving complex in PSII.  Four electrons are subsequently extracted 
from two water molecules in the oxygen-evolving complex (OEC) which consists 
of a manganese-calcium cluster, causing the water to become oxidized to 
molecular oxygen (O2) and released into the atmosphere, while four protons are 
released into the lumen and four electrons are provided for the electron transport 
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chain. The electrons from water are used to re-reduce P680+ upon charge 
separation. The final electron acceptor in PSII is a mobile plastoquinone QB (PQ) 
which leaves PSII upon binding of 2 protons as plastoquinol (PQH2). Electrons 
are transferred via PQH2 to the cytochrome b6f complex which pumps protons 
across the membrane and reduces the electron transfer protein plastocyanin, or 
cytochrome c6 at the lumenal side which transfers the electrons to PSI. PSI 
catalyzes the second light-induced charge separation event. The excitation energy 
from the antenna chlorophylls is transferred to P700, the primary electron donor 
in PSI. Upon excitation, P700* donates an electron that is transferred along the 
electron transport chain to the terminal FeS cluster FB from which it is transferred 
to ferredoxin, the soluble electron transfer protein located on the stromal side of 
the membrane. Ferredoxin transfers the electron to ferredoxin-NADP+-reductase 
(FNR). Two ferredoxins dock subsequently to the FNR which reduces NADP+ to 
NADPH [2]. During these electron transfer processes a proton gradient is formed 
across the thylakoid membrane, creating a pH difference (∆pH) and 
electrochemical membrane potential. ∆pH and ∆ψ gradient drive the synthesis of 
ATP, via a rotational mechanism of the ATP synthase [F0F1]. ATP and NADPH 
are the high-energy products that drive synthesis of carbohydrates in the dark 
reactions of photosynthesis (the Calvin Cycle).   
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Figure 1.1. (A) A schematic of the electron transfer chain of photosynthesis and 
critical proteins involved in photosynthesis, and the electron transport chain (B). 
Figure used with permission from Dr. Petra Fromme. 
 
1.2. Evolution of Oxygenic Photosynthesis and the Relevance of Photosystem II 
Prior to the evolution of cyanobacteria 2.5 billion years ago on Earth, an 
anoxygenic environment persisted. Eventually, evolution of biomolecules such as 
pigments took place, which paved the way for the first anoxygenic photosynthetic 
organism to develop ~3.5 billion years ago by the use of water as an electron 
source for the photosynthetic transport chain. [3] Around 2.5 billion years ago, 
oxygenic photosynthesis was initiated and gave rise to new biosynthetic 
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pathways. Cyanobacteria thereby evolved 2.4 billion years ago from non-
oxygenic photosynthetic ancestors, which resulted in oxygen production in the 
atmosphere. There are many current hypotheses for the invention of oxygenic 
photosynthesis; however it is known that O2 appeared in the atmosphere 2.4 
billion years ago, and many organisms were forced to adapt to the conditions. The 
“great oxygenation event” occurred between 2.0 and 2.4 billion years ago [4], 
when atmospheric oxygen increased to 1-2% and remained stable until 850 
million years ago, when oxygen concentration in the atmosphere increased to 
20%, as it remains today [3]. PSII is the protein responsible for oxidizing water 
into molecular oxygen, and without this, humans and other oxygen-dependent 
organisms would cease to exist.   
 
1.3. Strucure of Photosystem II (PSII) 
The initial light-driven charge separation events in oxygenic 
photosynthesis are catalyzed by two large membrane complexes: Photosystem II 
(PSII) and Photosystem I (PSI). Cyanobacterial PSII consists of 19 
transmembrane subunits, including core reaction center proteins D1 (PsbA) and 
D2 (PsbD), core antenna proteins CP43 (PsbC) and CP47 (PsbB), and more than 
50 cofactors. Cyanobacterial PSII also contains 3 extrinsic proteins (more 
extrinsic proteins are present in eukaryotes) which are critical in stabilizing the 
4MnCa cluster and have been shown to be necessary for oxygen evolution – a 33 
kDa “basket” shaped protein, PsbO, PsbV, and PsbU in cyanobacteria. Several 
pigments are also associated with PSII – 35 chlorophyll molecules, two 
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pheophytins, two plastoquinones, one non-heme iron, two hemes, and 11 β-
carotenes. Additionally, more than 20 lipids are bound to PSII. The OEC contains 
four manganese atoms and one calcium atom. Furthermore, 2 Cl- ions are located 
in the vicinity of the 4MCa cluster. Inaddition, two more Ca2+ and one more Cl- 
have been identified in the most recent x-ray structures of PSII [5,6]. In nature, 
PSII is a dimer. The PSII monomer is 350 kDa in size, spanning about 10.4 nm 
(4.5 nm of which is in the membrane). The diameter of PSII is approximately 10 
nm across. The dimer is found in all organisms. Monomers also exist but are very 
likely assembly intermediates. The dimensions of the dimer are 104 Å deep (45 Å 
is in the membrane), 205 Å long, and 110 Å wide.  
 
Figure 1.2. Photosystem II dimer depicting its subunits and environment 
surrounding the Mn cluster. Figure taken from reference [7] 
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1.4. PSII: Electron Transport Chain and its Role in Oxygenic Photosynthesis 
PSII is the key protein in oxygenic photosynthesis because it is 
responsible for extracting the electrons from water that are utilized further down 
the electron transport chain. In addition, molecular oxygen (O2) is a product of the 
water-splitting reaction and 4 protons are released into the lumen thereby 
contributing to the formation of the ΔpH gradient across the membrane. The sum 
reaction of water oxidation is given by: 
2H2O  O2 + 4H+ + 4e – (in the presence of light) 
Remarkably, PSII’s main pigments responsible for catalysis of the charge 
separation, P680, are highly oxidizing, possessing a redox potential of +1.1V (in 
standard electrochemical conditions). This redox potential is one of the strongest 
oxidizing species known in a biological system.  
The D1 and D2 membrane intrinsic subunits of PSII are responsible for 
forming the dimeric core and binding the cofactors of the electron transport chain 
(ETC). The PSII ETC consists of four pseudo-symmetrically oriented 
chlorophylls, two pheophytins, and two plastoquinones, as shown in Figure 1.3.  
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Figure 1.3. Detailed view of the electron transport chain in PSII. There are two 
branches shown in the electron transport chain, the D1 branch and the D2 branch. 
Figure taken from reference [8] 
 
Upon excitation and energy transfer from the antenna chlorophylls, charge 
separation occurs at P680, the primary donor chlorophyll pair. Then one electron 
is accepted by the monomeric chlorophyll of the D1 branch and subsequently the 
pheophytin molecule on the D1 branch. Once the pheophytin is reduced, electron 
transfer proceeds to the tightly bound plastoquinone (QA)  from where it is 
transferred to the mobile quinol PQ in the QB site, Once QB is doubly reduced by 
2 charge separation events, QB is released as a neutral plastoquinol (PQH2) into 
the membrane and replaced by a PQ from the pool of PQ molecules which is in 
the membrane. P680 is re-reduced by the OEC and this process is mediated by a 
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redox-active tyrosine residue (YZ) of the D1 protein. (Y161). Four photochemical 
turnovers provide the OEC with four oxidizing equivalents which drive it through 
the S-state cycle. Molecular oxygen is released during the S4 to S0 transition. [6,8] 
 
1.5. Structure of the OEC 
 Many different techniques have been used in order to understand the 
structure of the OEC. It is known that the cluster is composed of four Mn atoms, 
five oxygens, and one calcium. A cubane-like structure is formed from three of 
the manganese atoms, one calcium, and four oxygens. The fourth Mn is linked to 
the cubane via a µ-oxo bridge [5], as shown in Figure 1.4 below. The amino acids 
that play an integral role in stabilizing the Mn cluster are depicted in green (from 
the D1 subunit) and pink (from the CP43 subunit). Glu189 provides one ligand to 
the Mn cluster, while Asp170, Glu333, Asp342, and Glu354 as shown below 
provide bidentate ligands to the Mn cluster [5]. His337 is linked to the cluster 
through an oxygen atom. 
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Figure 1.4. Structure of the manganese cluster in PSII to 1.9Å resolution, 
revealing how the critical amino acids ligate the Mn cluster. Figure taken from 
reference [5] 
 
1.6. S-state Cycle of PSII and the State of the Manganese (Mn) Cluster 
Probably the most elusive mechanism in nature is the S-state cycle in PSII. 
This is the cycle in which four successive light-driven turnovers result in 
oxidation of 2 water molecules and the formation of O2. This mechanism is very 
sophisticated, and has been occurring for 2.5 billion years. In this mechanism, 
four oxidizing equivalents (most likely the mechanism is that in each step one 
proton and one electron are extracted) are accumulated at the OEC before O2 is 
released. The OEC consists of four manganese atoms, five oxygen atoms, and one 
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calcium atom forming the Mn4CaO5 cluster. Three manganese, four oxygen, and 
one calcium atom form a cubane-like structure in the highest resolution (1.9Å) x-
ray structure of PSII to date. (See Figure 1.4). However, the x-ray exposure 
reduces the Mn cluster, so whether or not the structure really represents the dark 
state is controversial. Many published EXAFS and XAS studies have explored the 
structure and mechanism of the MnCa cluster as well [9]. Furthermore, many 
models exist for the actual mechanism of water oxidation 
[10,11,12,13,14,15,16,17] but without an x-ray structure of the cluster in different 
S states it is still unknown how the actual water splitting mechanism works as the 
structures of each of the intermediates in the S-state cycle are still unresolved. 
This is the motivation for the PSII crystallization reported later in this work. A 
schematic of the S-state cycle is shown in Figure 1.5.  
 
 
 
 
 
 
 
 
 
Figure 1.5. Schematic of the S-state cycle, as first described by Bessel Kok, et al 
[18,19]. This is a four-electron process, in that four electrons must be extracted 
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from water to evolve one molecule of oxygen. Oxygen is evolved in the S4 – S0 
state.  
 
1.7. Photodamage of PSII and In Vivo Repair Mechanisms 
Excess energy, causes photodamage of PSII which is primarily caused by 
the triplet formation of P680. [20] However, even under moderate light conditions 
where no photoinhibition occurs, the chance of photodamage in PSII is roughly 
one in a million. PSII’s subunit D2 is stable in the presence of light; however, D1 
is turned over in vivo every half hour in direct sunlight [2]. The D1 protein, 
encoded by the gene psbA, has a very intricate mechanism for replacement. First, 
it is important to mention that PSII is disassembled in the damage-repair cycle, 
during which D1 and D2 are decoupled, and biosynthesis of D1 occurs 
independent of D2 before the protein is reassembled by a translational coupled 
mechanism [21]. Research conducted on D1 revealed that the D1 protein is 
synthesized as a precursor polypeptide containing anywhere from a 5-16 residue 
C-terminal extension that when inserted into the thylakoid lumen is cleaved by a 
peptidase following the light-induced assembly of two Mn atoms.  The peptidase 
responsible for this process is CtpA, and studies have shown that without this 
cleavage process occurring, no oxygen-evolving activity was observed. In prior 
studies, it was found that the mature D1 protein is 2 kDa smaller than the 
precursor polypeptide, indicating that cleavage of a significant portion of the 
polypeptide occurs [22]. Figure 1.6 below shows the process of D1 turnover.   
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Figure 1.6. Damage-repair cycle of the D1 subunit of PSII. Figure taken from 
reference [21]. PSII has an elaborate repair mechanism which consists of the D1 
and D2 subunits being decoupled (right side) in a degradation pathway, and D1 
being co-translated in the presence of D2 before re-assembling. 
 
 
This damage-repair cycle hinders the direct use of PSII for man-made water-
splitting devices. This work aims to design a construct that is not negatively 
affected by the sunlight by decoupling of the OEC and the light excitation 
processes. The generation of reactive oxygen species (ROS) due to triplet 
formation by P680 is likely the reason PSII has an elaborate damage-repair cycle, 
and our construct isolates and aims to build an artificial oxygen-evolving complex 
(aOEC) that can be coupled to an artificial reaction center that is based on the 
reaction center in PSII.  
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1.8. “Isolating” the aOEC from P680+ 
Extracting natural PSII from cyanobacteria or plants and using this in a solar fuel 
system is not possible due to PSII’s photodamage. This photodamage emanates 
from the reactive triplet formation of P680 [20], with P680 being responsible for 
the initial charge separation event in PSII. It would not be feasible to isolate and 
incorporate natural PSII into a solar to fuel system because in nature, the D1 
protein is degraded every 30 minutes in the presence of sunlight. Therefore, the 
final goal of the Energy Frontier Research Center (EFRC) at ASU is to design a 
clean solar-to-fuel system that is based on nature. There are 5 subtasks that work 
on a critical part of the solar-fuel system, and ours focuses on rebuilding the OEC 
in a more stable environment so it can serve as an electron donor.  
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Figure 1.7. Schematics of both the D1 subunit and CP43 extrinsic subunit of 
PSII. Each cylinder represents a transmembrane helix. The Mn cluster ligands are 
shown in green (left) for the D1 subunit, and in red (right) for the CP43 subunit. 
These amino acids provide ligands to the Mn cluster and are used in our construct 
which aims to synthesize peptide sequences containing these critical amino acids. 
All of the critical amino acids are on the lumenal side of the membrane.  
 
   
   
1.9. Deoxyribonucleic Acid – From Genetic Material to its Use in 
Nanoengineering – Why Use DNA as a Scaffold? 
The structure of B-DNA was solved in 1954 by x-ray crystallography [23]. Over 
the past 60 years, not only do we know the structure and function of this 
macromolecule as a genetic tool, but we are now using it as a platform for 
nanoengineering a broad range of biological systems. The physiochemical 
stability and repeating helical structure of DNA offers a molecular framework for 
designing functional materials for drug delivery [24], nanomechanical devices 
[25], and synthetic catalysts [25]. DNA offers desirable characteristics like 
sequence specific base-pairing that allow for its use as stable frameworks in 
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nanotechnology [26,27]. The physiochemical stability of DNA makes it a 
desirable candidate for designing nanostructured materials as DNA is inherently 
nanoscalable. Double-stranded DNA (dsDNA) readily hybridizes in a highly 
reproducible process. Strands are separated at a 90°C peak temperature followed 
by a cooling step which facilitates the hydrogen bonding between the 
complementary bases adenine-thymine and guanine-cytosine, and allows the 
dsDNA to relax into its characteristic helical B-DNA structure. Structural 
building blocks comprised of DNA offer even more stability than protein-based 
scaffolds [28]. Because of the reproducibility of experiments and well-established 
protocols present in DNA technology, diverse 3-dimensional nanostructures have 
been previously designed [28,29], including a tetrahedron structure with 20 bp 
edges (20T tetrahedron) [29]. The pioneering work of Seeman and colleagues 
showed the first structure of a DNA crystal lattice formed by annealing [30]. Prior 
characterization of the 20T tetrahedron included a 8 Å resolution cryo-electron 
microscopy structure [31], providing the overall topography and verifying the 
expected assembly of the structure. However, the resolution limit of cryo-EM 
prevents the distinguishing between diastereomers and does not allow for the 
identification of individual bases. The fairly large cavity size of the 20T (inner 
diameter of 7 nm) tetrahedron structure enables small proteins and designed 
functional molecules to be enclosed in the center of the construct. DNA   bases 
can be chemically modified to include many different linkers such as primary 
amines, thiols, dyes, polyethylene glycols, and carbon chains to serve as 
attachment sites for peptides, proteins, and nanoparticles. Prior published work 
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involving 3D DNA scaffolds includes the encapsulation of proteins, peptides, 
nanoparticles [32,33], dyes [34], and redox-active components [35]. Prior 
research utilizing these conjugation strategies include  the encapsulation of 
cytochrome c in the center of a 3D DNA tetrahedron [36], the introduction of a 
two-dimensional scaffold of tetrahedra [30,37],  and incorporation of the 
tetrahedron into antimony-doped tin oxide porous material [38]. A rationally 
designed three-dimensional network has many useful applications, especially 
having the ability to host macromolecules in a periodic array, similar to a crystal 
lattice [37,39]. Additionally, encapsulating redox-active proteins or molecules 
inside of the tetrahedron would allow for the use of the system for electron 
transfer reactions. Organizing functional proteins and biomolecules inside of 3D 
DNA-based nanostructures also offers the potential for catalytic enhancement, as 
the framework serves as a stable network for molecules in solution .     
 
1.10. Structure Determination of Nucleic Acid Complexes 
The  PDB database (as of September 2012) reveals that of currently 65,950 
structures solved by x-ray crystallography, only 1,346 (1.9%) are of nucleic acids, 
and 3,261 (4.6%) are of protein-nucleic acid complexes. Most of the published 
DNA structures solved by x-ray crystallography are DNA-protein complexes, 
short DNA sequences, and tetraplexes. However, to date, no x-ray 
crystallographic structures of three-dimensional DNA nanostructures have been 
reported.  
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2. HYPOTHESES AND DISCUSSION 
2.1. DNA as a stable framework for engineering catalytic centers 
DNA possesses many characteristics that allow for its use as a stable 
framework in this work. The physiochemical stability is known to be greater than 
that of proteins and peptides [28,40], and the specificity of base-pairing allows for 
reliable and reproducible experimental procedures. Additionally, DNA can be 
functionalized through many different chemical modifications; therefore, different 
peptide sequences or proteins can have multiple conjugation sites within the DNA 
tetrahedron. In this work, a three-dimensional DNA tetrahedron has been used as 
the stable framework for encapsulating peptides and cofactors. Four 63-base long 
oligonucleotides self-assemble to form the double-stranded tetrahedron, 
consisting of six 20 base pair edges, and four apexes which form the corners and 
are comprised of unpaired adenines. This nanostructure provides the structural 
framework to attach synthetic peptides that will coordinate cofactors. The 
ultimate final goal in the future of this project will be the assembly of the 
manganese cluster necessary for water oxidation inside the DNA nanocage. 
 
 
2.2. Engineering a complete solar fuel production system based on water 
oxidation 
A solar-based clean fuel system is necessary for human proliferation, as 
atmospheric CO2 levels continue to rise, leading to significant climate change. 
The continuously rising atmospheric CO2 levels have already left astronomical 
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footprints on our planet, as evidenced by the acidification of oceans and 
deterioration of carbonate coral reef systems [41], and the gradual shrinking of the 
arctic polar ice cap (National Snow and Ice Data Center: 
http://nsidc.org/arcticseaicenews/). Worse yet, atmospheric CO2 emissions are 
predicted to rise to over 500 ppm (parts per million) between the years of 2050-
2100 [41]. Rather than obtaining energy from hydrocarbons, solar energy can 
instead be harnessed using elaborate pigments that aid in capturing photons and 
transferring that energy to engineered catalytic systems based on what nature has 
already provided for us.  
Water oxidation in PSII serves as the basis for our design, providing four 
electrons, four protons, and molecular oxygen as products. The goal of the EFRC 
is to build an artificial leaf mimicking nature, but making the system more 
efficient and robust. By understanding and mimicking the photosynthetic electron 
transport chain (that already exists in nature), a system has been designed by the 
EFRC that uses the aOEC  as the Photosystem II mimic, the arc (artificial 
reaction center) as the reaction center mimic, the fpc (fuel production complex) as 
the hydrogenase mimic, and the nte (nanostructured, transparent wide band gap 
semiconductor electrode) as the transparent semi-conductor to absorb sunlight and 
aid the arc in promoting electron transfer. Protons produced from the oxidation of 
water by the aOEC are transferred through an ion-selective membrane to the 
proton reduction side of the system, where protons are reduced to hydrogen. See 
Figure 2.1 for an overview of the design.  
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aOEC design 
The first design of the aOEC is comprised of three peptide sequences that are 
coupled in 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Schematic of the solar to fuel system based on water oxidation, the 
core of the Energy Frontier Research Center at ASU. The aOEC is the PSII mimic 
which will utilize the electrons generated by the arc. The arc is the reaction center 
mimic and consists of porphyrins which will absorb the light, and the fpc is the 
fuel production complex and serves as the hydrogenase mimic. Furthermore, the 
nte (nanostructured, transparent wide band gap semiconductor electrode) serves as 
the transparent semi-conductor to absorb sunlight and aid the arc in promoting 
electron transfer. The ism, or ion-selective membrane, allows the protons 
produced from water oxidation to be transferred to the proton reduction side of 
the system, where protons are reduced to hydrogen. Figure courtesy of the 
BISFuel team at ASU. 
 
 
five different locations in the 20T tetrahedron. Specific linker chemistries such as 
click chemistry, maleimide-thiol linkages, and SMCC could be used to covalently 
attach the peptides to the tetrahedron. The peptide sequences are derived from the 
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natural peptide environment that coordinates the manganese cluster in PSII. The 
sequences are shown in Figure 2.2.  
 
 
 
 
 
 
 
 
 
Figure 2.2. The peptide sequences implemented in this work, all providing 
critical ligation sites to the active site of PSII, the oxygen-evolving complex. 
These sequences will comprise the synthetic OEC described.  
 
The green sequence is 34 aa long and consists of the C-terminal region of the D1 
(PsbA) subunit of PSII (CT-D1) from Ala318-Ala344 and contains 4 ligation sites 
to the manganese cluster. The yellow sequence is also based on PsbA and is 40 aa 
long spanning from Ala156-His195 (156-195-D1) and is the lumenal loop 
between transmembrane helices d and e, which includes the redox-active TyrZ 
(Tyr161) and provides 3 ligation sites. Lastly the red sequence is 14 aa long and is 
designed based on the CP43 extrinsic protein subunit of PSII from Gly347-
Asp360 (347-360-CP43), spanning the lumenal loop between helices e and f and 
provides one metal ligation site. Figure 1.7 shows the location of the peptide 
sequences in the PSII dimer. The final goal of this work is to build the 4MnCa 
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cluster with its surrounding ligands inside DNA nanocages. The synthetic 
peptides must have individual conjugation sites within the DNA tetrahedron and 
should be covalently attached to provide stability. The goal for the peptide 
conjugation is to covalently couple the peptides to the single-stranded DNA 
oligonucleotides first, and then anneal the sequences to form the DNA 
tetrahedron. Therefore, conjugation strategies must be employed that are specific 
and temperature tolerant due to the high temperature used for annealing (90°C).  
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic of the aOEC encapsulated inside of a 20 bp tetrahedron 
comprised of dsDNA. Each peptide sequence shown plays a critical role in water 
oxidation in nature and we hope to achieve the goal of water oxidation in this 
stable synthetic system. Figure courtesy of Chenxiang Lin.  
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3. THEORY OF ANALYTICAL METHODS 
 
3.1. Dynamic Light Scattering (DLS) 
 
3.1.1. Theory 
Light has both magnetic and electric properties, and when it interacts with 
a particle, it results in an induced dipole that oscillates and emits radiation. The 
emitted radiation is called “scattering”. In solution, particles behave in a random 
manner, known as Brownian motion [42]. The Brownian motion of particles is 
affected by the particle size, the electric charge, shape, and abilities to bend or 
twist. When the light is scattered from the moving particles, it can be either 
constructive or destructive, depending on where the particles are in relation to one 
another. The interference between the scattered light changes as the particles are 
moving in solution, thereby causing fluctuations in the intensity of the scattered 
light [43]. Larger particles move slower in solution and therefore give slower 
fluctuations of scattered light, while smaller particles move faster and give faster 
fluctuations of scattered light [43]. There are three major types of light scattering 
– dynamic light scattering, static light scattering, and Raman scattering. Dynamic 
Light Scattering (DLS) is the technique used in this study so the focus will be on 
the theory of DLS. Upon detecting the fluctuations of the scattered light 
intensities, a diffusion constant can be derived using an autocorrelation function 
based on the measured intensities [44]. The software programs used in this study 
as designed by Dierks, et al. [45] typically use this diffusion constant to calculate 
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the hydrodynamic radius distribution in the measurements, based on the Stokes-
Einstein equation 
 
Rh = kT_ 
6πηD 
 
where Rh is the hydrodynamic radius, k is Boltzmann’s constant, T is the 
temperature in K, η is the viscosity of the solution, and D is the diffusion 
constant. The measurements reveal a molecular weight of the sample based on the 
chosen parameters, such as the solvation sphere, density, and shape of the 
molecule, and also the viscosity of the solution. These properties are important as 
they significantly affect the observed molecular weight.    
The experimental setup is shown below in Figure 3.1 and involves the use 
of a red laser (in this case 785 nm) that is aligned with the detector in a small 
volume of concentrated sample around 1-5 µL on a glass cover slide that is 
typically used for a hanging-drop vapor diffusion crystallization experiment. The 
sample is easily recoverable after measurements, which also makes DLS a 
desirable technique to use for pre-crystallization characterization. The DLS 
measurements give a distribution of hydrodynamic radii of the sample, along with 
the corresponding molecular weight. In order to obtain the molecular weight 
(MW) of the sample, the following equation is used. 
MW = (Rh – rw)3 NA • (4π/3ν) 
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Where NA is Avogadro’s number, rw is the particle radius contribution, ν is the 
partial specific volume (the inverse of density), and Rh is the hydrodynamic radius 
[43,44].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. DLS setup using a small sample volume. A schematic of the setup is 
shown at the top, and the bottom shows an image of the instrument, a Molecular 
Dimensions SpectroSize 302. With this instrument, the angle between the laser 
pathway and scattered light, θ, can be varied.  
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3.1.2. Applications 
DLS has many useful applications, one of them being very important to 
macromolecular crystallography. Considering that crystallization experiments 
require pure monodisperse samples, a technique is necessary to identify possible 
contaminants during sample preparation. DLS can detect the homogeneity of a 
protein sample and identify the aggregation state of a protein before any 
crystallization experiments are even attempted, allowing for earlier detection of 
problems arising in the sample preparation phase, especially aggregation, that 
would hinder the production of quality crystals. The aggregation state of the 
protein and any impurities can not only be identified in a sample [46], but also 
quantified through DLS. Over the last few years, improvements in DLS 
technology have lead to more sophisticated instruments [45] that have many more 
adjustable parameters for viscosity, molecular density, and shape factor - all of 
which drastically change the outcome of the size and molecular weight 
distribution determined by DLS. Some commercially available instruments like 
the instruments from Wyatt Technology do not have such manual input of 
parameters. The improved instruments are particularly important for novel 
rationally-designed macromolecules and in particular, DNA nanoarchitectures 
which need to be characterized and do not necessarily have the same density as a 
spherical protein. We use a novel design by Dr. Karsten Dierks, commercialized 
by Molecular Dimensions. Additionally, the pioneering work of K. Dierks et al 
involves the use of DLS to actually measure the size distribution of particles in 
the crystallization drop over time, indentifying the nucleation event, the 
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developing crystals, and the formation of precipitate. Given that aggregates were 
visualized shortly after setting up the crystallization experiment, the researchers 
were able to identify the nucleation threshold (once the aggregates stopped 
growing) and degree of supersaturation of a sample [45]. This DLS method can 
not only be used for pre-crystallization but also for monitoring the nucleation 
events in the crystallization in progress, determining the rate of crystal growth. 
 
3.2. X-Ray Crystallography 
3.2.1. Theory and Background 
X-ray crystallography is a powerful technique to study a molecule’s 
structure at atomic resolution. In solving the high resolution structure of 
macromolecules, we have improved our understanding of how biochemical 
pathways function, improved drug-ligand specificity, and revealed many other 
important mechanisms in biology [47]. Currently, 75,146 structures (biological 
macromolecular structures) solved by x-ray crystallography are deposited into the 
Protein Data Bank (www.rscb.org/pdb/statistics) as of October 2012. So far, in 
2012 alone, 6800 x-ray structures were solved. Currently, only 9,680 NMR and 
464 EM (electron microscopy) biological macromolecular structures in total have 
been solved.  
 
3.2.2. Crystallization 
X-ray crystallography involves the study of proteins and other 
macromolecules in their crystalline state. The first step of crystallography 
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involves devising a method and a set of conditions to crystallize the target 
macromolecule so it can be used in x-ray crystallography experiments. Without 
crystals, x-ray diffraction is limited to Small Angle X-Ray Scattering (SAXS) 
[48] and Wide Angle X-Ray Scattering (WAXS) studies [49] which so far do not 
allow for atomic resolution structures of large biomolecules to be determined. The 
crystallization step can often be the bottleneck in solving the crystal structure of a 
large biomolecule like a protein or DNA construct. Crystallization experiments 
often require many trials, and so sample preparation can also be a limiting factor. 
The molecule needs to be crystallized in a periodic array or lattice to allow for the 
x-rays to diffract on the lattice planes, according to Bragg’s law 
2dh,k,l sin θ = n λ 
 
where d is the distance along lattice planes h, k, l, θ is the reflecting angle, and n 
is an integer [47]. When the x-rays are diffracted from the crystal lattice, they 
produce a diffraction pattern from which a series of well-developed mathematical 
formulas are employed to obtain an electron density map, revealing each atomic 
position in a molecule.  
 Wave functions are used to describe the x-ray reflections, and a structure 
factor equation is the term used to describe a diffracted x-ray. The sum of the 
reflection hkl is called the structure factor, Fhkl. Fhkl is a term of the superimposed 
wave functions for every atom. Thus, every atom in a molecule contributes to 
every reflection in the diffraction pattern [50]. The sum is written as 
Fhkl = ƒA +ƒB + ….. + ƒA’ +ƒB’ + ….+ ƒF’ 
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in which the A’, B’, and F’ values are the reflections. From the Fourier sum, the 
electron density is calculated, written as ρ(x,y,z).  
The equation that relates the electron density to the diffraction pattern is 
 
 
 
in which all of the reflections and phases are accounted for [50]. What many 
crystallographers commonly refer to is the “phase problem”, in which the electron 
density cannot be directly obtained from a data set of diffraction patterns unless 
the atomic coordinates are already known. (See description of Molecular 
Replacement below). The “phase problem” in crystallography arises from the 
inability to distinguish between the periodic waves that comprise the reflections 
from the atoms. In a general description, structure factor amplitudes are obtained 
from the reflection intensities, and the structure factors are not directly obtainable 
from the reflections because the phase of each x-ray is unknown [50].  
Therefore, there are several methods to overcome the phase problem – 
Molecular Replacement (MR), Multiwavelength Anomalous Diffraction (MAD), 
Single Isomorphous Replacement (SIR), and Multiple Isomorphous Replacement 
(MIR). In MR, the atomic coordinates from a homology model of a similar 
structure are used to solve the phases. In MAD, data sets are obtained at the heavy 
atom’s absorption edge. Thus, multiple wavelengths of x-rays are scanned. 
Because of the different wavelengths of x-rays that the heavy atom derivatives 
absorb, Friedel’s law does not hold and the reflection intensities are unequal. 
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Thus, in MAD, intensities of Friedel pairs are measured in the data set [50]. In 
SIR and MIR, heavy-atom derivatives are prepared. In SIR, one heavy atom is 
used, and in MIR, more than one is used. Selenomethionine derivatives, for 
example, are prepared during the protein expression phase. In other cases, the 
crystals are soaked in mercury, iodine, platinum, or gold which bind to specific 
sites in the protein crystal and are used to obtain the phases.   
Crystallization is a phase separation process. In order to crystallize a 
molecule, the most widely used method involves using a precipitant. Through 
evaporation in vapor diffusion, the water molecules will slowly be removed from 
the solution so that the concentration of both the protein solution and the 
precipitant are increased in the crystallization drop [47]. As the water is removed, 
the protein solution becomes supersaturated and the molecules are forced out of 
solution. This could lead to amorphous precipitate as the molecules align together 
a certain way, ideally in a lattice. The crystallization process is depicted in a phase 
diagram in Figure 3.2. Crystallization is initiated through a nucleation event, or 
the formation of a “seed”. The formation of the “seed” causes the radius to exceed 
the critical radius rc. The supersaturation point where the nuclei reach rc is marked 
by the nucleation zone. The protein is effectively forced out as a precipitate or as 
a crystal, which, if thermodynamically possible, may cause a phase change from 
the solution to the crystalline state. It is during this step that crystals form in the 
nucleation zone [47]. By formation of crystals, the soluble protein content 
continues to decrease, which causes the system to be moved into the metastable 
zone. In the metastable zone, pre-formed crystals can grow, but no new nucleation 
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events occur. This zone is therefore ideally suited for growth of large, well-
ordered crystals from pre-formed seeds. The crystallization process continues 
until a kinetic equilibrium is reached between the soluble protein and the 
crystalline protein. The formation of showers of tiny crystals is a result of many 
nucleation events occurring at one time. Additionally, if the protein and 
precipitant concentration are too high, amorphous precipitate can form in the 
precipitation zone. Therefore, the method of obtaining diffraction-quality crystals 
is time-intensive and requires many trials with different precipitant, salt, and 
buffer systems to achieve the best crystals.   
 
Figure 3.2. Crystallization phase diagram indicating the initial nucleation event 
(dark blue arrow) and subsequent decrease in soluble protein concentration by 
crystal growth, which brings the system into the metastable zone (purple arrow) 
where crystallization continues until the soluble protein and crystalline protein 
reach an equilibrium, as indicated by the purple arrow pointing to the interface of 
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the soluble and metastable zones. The x-axis indicates precipitant concentrations 
which could be salt, PEG, organic solvents, etc.  
 
 
There are quite a few different techniques used for crystallization - vapor 
diffusion, batch crystallization, microdialysis, and free-interface diffusion. In this 
study, vapor diffusion (20T tetrahedron) and batch crystallization (PSII) were 
performed; therefore, they are described in detail in this text. Vapor diffusion 
methods require the mixing of protein and reservoir solution (screen solution 
containing a buffer, salt, and precipitant) in a small volume (1-5 µL) on a cover 
slide or in a sitting drop in a protein “well”. The cover slide is sealed on top of a 
reservoir containing 500-1000 µL of the screen solution which contains a larger 
concentration of total molecules than the protein drop. Over time, the water in the 
protein drop evaporates, increasing the concentration of both protein and 
precipitant in the protein drop, and crystals form in the drop. As the volume of the 
reservoir is much larger than the volume in the drop, the “dilution” of the 
reservoir solution can be neglected and the concentration is thereby approximately 
constant. The concentration gradient between the drop and reservoir determines 
the final concentration factor of the protein drop. 
In the batch crystallization method, the protein solution is mixed with the 
precipitant solution. This is usually done in a capillary tube, where the sample 
starts in the nucleation zone, and as the protein concentration decreases, the 
system moves to the metastable zone [51]
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must be known. Furthermore, seeding with pre-formed crystals can be applied so 
that crystal growth directly occurs in the metastable zone. 
The crystals are then incubated in cryoprotectants and frozen in liquid 
nitrogen before beginning x-ray diffraction experiments at either a home source or 
a synchrotron. Radiation damage has always been a prominent issue in 
macromolecular crystallography; therefore, the use of cryocooling of crystals 
began approximately 20 years ago after realization that there was significant 
radiation damage to the crystal in the presence of x-rays at room temperature [52]. 
X-ray damage causes the disruption of disulfide bonds, decarboxylation of 
asparates and glutamates, for example, and can also lead to reduced quality in 
diffraction patterns [52]. Additionally, the radiation damage problem is 
particularly significant when working with the current generation of synchrotron 
radiation sources compared to a home x-ray source such as a rotating anode, as 
the x-rays are more brilliant at the synchrotron [50], as shown in Figure 3.3 
below. 
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Figure 3.3. The photon energies and average spectral brightness of the x-rays 
produced by a rotating anode compared to x-rays produced by synchrotron 
radiation. The average spectral brilliance is much greater in the newest 
synchrotron sources, as seen at the top of the graph. Figure taken from reference 
[53].  
 
Because it is necessary to rapidly freeze protein crystals, ice formation 
becomes an issue. Therefore, cryoprotectants were implemented to avoid ice 
formation during the freezing process. The most common method of freezing 
involves plunging the crystal into liquid nitrogen after incubating in 
cryoprotectant solutions. Other methods include using liquid propane and ethanol. 
The formation of ice damages the crystal and also the diffraction pattern [50]. 
Thus, cryoprotectants play a key role in solving a high-resolution structure of a 
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biological macromolecule. A schematic of a synchrotron is shown below in 
Figure 3.4, and images from a synchrotron facility are shown in Figure 3.5.  
 
Figure 3.4. Schematic of a synchrotron. Synchrotron radiation is necessary for 
obtaining very high-energy photons (λ = ~1Å) focused into a small beam 
(sometimes as small as 5-10 µm in diameter [54] for microfocused beam 
experiments on tiny crystals) to obtain the highest-resolution structure possible. 
Image from http://geographyfieldwork.com/SynchrotronWorks.htm. 
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Figure 3.5. Images from Beamline ID-19 at the Structural Biology Center at the 
Advanced Photon Source (APS) at Argonne National Laboratory. Behind the door 
in the image on the left is the actual x-ray source. The image on the right shows 
the outside of one small section of the storage ring, depicting the large size of the 
synchrotron facility. 
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3.3. EPR 
3.3.1. Background and Theory 
Electron Paramagnetic Resonance (EPR) involves the study of paramagnetic 
species (compounds with unpaired electrons). Unlike Nuclear Magnetic 
Resonance, where the operating frequency is varied and the magnetic field is kept 
constant, EPR involves applying a varying magnetic field and keeping the 
operating frequency constant. Rather than studying nuclear transitions as in NMR, 
in EPR the electron transitions are studied. During EPR, molecules, ions, or atoms 
that contain paramagnetic species absorb radiation of microwave frequency. The 
unpaired electrons interact with the applied magnetic field, B, and are excited to 
the upper energy level. This interaction is referred to as the Zeeman effect. [55] 
See Figure 3.6. Because of the electron’s excited state lifetime, the temperature 
during an EPR experiment is conducted in very low temperatures in the presence 
of liquid helium or nitrogen (between 4-77K). There are three main equations that 
explain the interaction of the magnetic field and the unpaired electrons, and they 
are shown below 
(1) µ = -gβS 
(2) E = µβ 
(3) ∆E = hν 
where µ is the magnetic moment of the electron, β is the Bohr magneton, S is the 
total spin associated with the electron, h is Planck’s constant, and ν is the 
frequency of the electromagnetic wave, E is the energy of a photon, and g is the 
spectroscopic splitting factor. From these equations and from applying the 
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constant frequency during the measurements (only the magnetic field is variable 
in EPR), one can calculate the g value based on 
(4) g = hν/βBR 
 
where BR  defines the resonance condition. The resonance condition is defined as 
the point at which the applied magnetic field causes the energy of the transition to 
become resonant with the magnetic field. The g value is defined as the magnetic 
intensity at which the EPR absorption is at a maximum as the magnetic field is 
varied and ranges from less than 1 up to 18 [55]. The absorption curve is 
displayed as the first derivative in order to reveal more details of the spectra. See 
Figure 5 below for a schematic of EPR measurements. In this study, the frequency 
was 9 GHz (referred to as “X” band), and continuous wave (CW) EPR was used.  
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Figure 3.6. Diagram depicting the technique of EPR. Microwave irradiation of a 
sample causes an electron to become excited to a higher energy level, and this 
happens when the applied magnetic field, B, shown in the x-axis, is equal to the 
field of resonance. The energy increase is indicated by a peak. Although this 
figure depicts an energy diagram, the magnetic intensity at which the EPR 
absorption is at a maximum as the magnetic field is varied gives the g value, 
which would have absorption on the y-axis. EPR absorption spectra are shown in 
first derivative form, as shown in the inset.  
 
 
 
EPR is a very valuable technique when studying proteins that contain metal 
centers. Metalloproteins are central to redox chemistry, which is essential to a 
cell’s function. The redox state of proteins can be studied using this technique, 
which sheds light on their function. In this study, EPR is used to analyze the 
coordination of a transition metal, iron(III) by two axial ligands, identifying the 
characteristic spin-state change upon binding.  
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4. MATERIALS AND METHODS 
 
4.1. PSII ISOLATION AND PURIFICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Flowchart briefly outlining each of the steps involved in PSII 
purification. The asterisks (*) indicate that a chlorophyll determination test is 
necessary before proceeding to the next step.  
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4.1.1. Cell culture 
Photosystem II was isolated from the cyanobacterium 
Thermosynechococcus elongatus (T. elongatus) in a series of steps. This 
cyanobacterium is grown at a temperature of 56°C in a large-scale bioreactor (See 
Figure 4.2.) which holds approximately 120 L of cell culture. The reactor is 
operated in a quasi-continuous mode where ~50 L of cell culture are harvested 1-
2 times per week in the logarithmic growth phase of the cells. ~20-30g of wet cell 
pellets are obtained from one harvest. The cells are frozen as a dense pellet at -
80°C until use. 
 
4.1.2. Cell disruption 
Typically, between 20-25 g (enough for two FPLC runs) of frozen cells 
(stored at -80°C) were placed in a 220 mL centrifuge vessel and thawed in PREP1 
buffer in a water bath with a temperature of 52°C and shaken from time to time 
until all cells were suspended. This thawing process is used because the intact 
cells are not stable between 4-8°C. The intact cells were centrifuged (Sorvall, 
Brea, CA, USA) in the 220 mL centrifuge vessel using a SLA-1500 rotor 
(Beckman Coulter, Brea, CA, USA) at 7,000 rpm at 24°C for 10 minutes. A 
paintbrush was used to remove the orange layer on top of the pellet containing 
spirillum cells which are a symbiont of the T. elongatus. The cells are disrupted 
using a microfluidizer (Microfluidics Model M-110L, Newton, MA, USA) where  
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Figure 4.2. The bioreactor used to grow the thermophilic cyanobacteria, T. 
elongatus, which holds approximately 120 L of cell culture. The cells are grown 
at 56°C.  
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cell rupture is achieved through high shear-forces at 9,000-13,000 psi. The 
microfluidizer was flushed with water and then PREP2 with the pressure 
reduction valve between 85-90 psi and a working pressure of 9,000 psi. Ice was 
placed on the microfluidizer coil prior to starting the flushing procedure in order 
to cool down the system. The sediment of cells from the centrifugation run was 
homogenized in 100 mL PREP2 + 1 mM PMSF before passing through a sieve 
and loading into the microfluidizer. The cells were passed through the 
microfluidizer twice at a pressure of 9,000 psi. Since the cells are very resilient to 
higher temperatures, the cell wall is very difficult to break and so two 
microfluidizing steps are necessary to break <90% of the cells. The microfluidizer 
was immediately flushed with 500 mL of water and then 100% isopropanol to 
prevent any clogging from cells left in the system. The centrifuge beaker 
containing the broken cells was filled with ice cold (4°C) PREP1 and centrifuged 
in a SLA-1500 rotor at 14,000 rpm for 10 minutes at 4°C to remove undesired cell 
contents. 
 
4.1.3. Thylakoid preparation 
The next few steps involve isolation of the thylakoids. The sediment was 
homogenized in 600 mL ice cold PREP1 and centrifuged in the SLA-1500 rotor at 
11,000 rpm at 4°C for 10 minutes and this step was repeated once again. Then the 
pellets from the two centrifuge vessels were homogenized and combined. 200 mL 
ice cold PREP1 was added and the sample was centrifuged in the SLA-1500 rotor 
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at 11,000 rpm at 4°C for 10 minutes. The resulting pellet was homogenized in a 
small amount of PREP3 to achieve a concentration of at least 1 mM chlorophyll.  
 
4.1.4. Chlorophyll determination 
Four 1.5 mL reaction vessels were prepared with 635 mg 100% acetone 
and 199 µL water. Chlorophyll content was quantified by adding 1 µL of the 
sample in three of the four tubes, vortexing, and centrifuging in a microcentrifuge 
for 3 minutes at 12,000 rpm. In this step the chlorophyll is extracted, while the 
denatured protein and phycobilisomes are precipitated. The bluish colored pellet 
was visible along with a green supernatant. The supernatant was pipetted into a 
cuvette to measure the chlorophyll concentration. The chlorophyll concentration 
was determined by taking the molar extinction coefficient of ε = 76,780 [56] into 
account as 
 
[(A664 – A700)/76,780] x 1000 (in molar).  
 
The chlorophyll concentration was adjusted to 0.75 mM with PREP3. 
 
4.1.5. PSII solubilization 
PSII was extracted in PREP3 containing 1% β-DDM and 1 mM PMSF. 
The solution volume was typically between 150-250 mL and was stirred at room 
temperature for 45 minutes in the dark. In this step, the solubilization of PSII from 
the thylakoid membranes takes place, where PSII is extracted in the form of a 
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protein-detergent micelle. The solution was divided into 8 centrifuge tubes for the 
ultracentrifugation step and placed into a 70Ti rotor (Beckman Coulter, Brea, CA, 
USA). The samples were centrifuged at 4°C for 1.5 hours at 50,800 rpm.  
 
4.1.6. Purification of PSII by anion-exchange chromatography 
The supernatant was collected from each tube (typical total volume was 
200 mL) and purified by anion-exchange chromatography (AEC) using a FPLC 
(Akta, GE Healthcare, Piscataway, NJ, USA). The column (XK 26/70, GE 
Healthcare, Piscataway, NJ, USA) was packed with Toyo Pearl DEAE 650 S 
anion exchange material (Tosoh Bioscience). The column is 70 cm long, 26 mm 
inner diameter, and has a volume of 200 mL. The column was washed with 100% 
buffer A150 at a flow rate of 10 ml min-1 for 10 minutes, and then equilibrated with 
10% buffer A150, 90% buffer A0 at a flow rate of 10 ml min-1 for 20 minutes.  
After the equilibration, the supernatant from the ultracentrifugation step was 
applied to the FPLC at a flow rate of 10 ml min-1. The fractions containing the 
purified PSII were pooled and applied to 100kDa MWCO ultra-filtration units 
(Millipore, Billerica, MA, USA) to concentrate the protein. The PSII was 
centrifuged at 4000 rcf at 4°C.  
 
4.1.7. PSII crystallization as the last purification step 
Following the concentration step, the chlorophyll concentration was 
analyzed, with the target concentration of 0.75mM for the first precipitation step. 
Buffer C was added accordingly if the sample was too concentrated. PSII was 
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precipitated with a series of three PEG solutions for approximately one hour per 
precipitation, each with different amounts of Buffers D0 and D20. Buffer D0 did 
not have any PEG-2000, while D20 had 20% (w/v) PEG-2000. For the first 
precipitation, the PSII was incubated for 1 hour with the first PEG-2000 
concentration, typically between 4-6%. The amorphous precipitate was 
centrifuged at 4000 rcf at 4 °C for about 5 minutes and the pellet was redissolved 
in Buffer C to obtain the target chlorophyll concentration of 0.75 mM. This step 
was repeated twice more, but with decreasing PEG-2000 concentrations. The 
PEG-2000 concentrations typically used were between 4-6%, and the amount of 
precipitant needed was calculated based on the chlorophyll concentration. In the 
third precipitation step, small crystals normally appear. The small crystals can be 
dissolved to yield the protein solution for further crystallization experiments. The 
crystals were redissolved in Buffer C to yield a chlorophyll concentration of 4 
mM for microbatch crystallization experiments.  
 
4.1.8. PSII Crystallization 
Microbatch crystallization experiments were set up with a starting PEG-
2000 concentration range between 4-10%, with increments of 0.5%, made by 
diluting a 40% PEG-2000 stock solution with Buffer D0. The microcapillary tubes 
used held 50 µL of sample. 15 µL of PSII was mixed with 15 µL of each PEG-
2000 solution for each concentration of PEG. Following crystallization of PSII, 
the crystals were incubated for 5 minutes stepwise in cryoprotectants ranging 
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from 0-30% (0,8,15,24,30%) glycerol in Buffer C. The crystals were then frozen 
in liquid nitrogen. 
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BUFFERS AND SOLUTIONS USED FOR PSII PREPARATION 
Tocopherol stock solution 
0.5 M tocopherol in ethanol (10 mL) 
 
PREP1 – 2L 
20 mM MES pH 6.0 
10 mM calcium chloride 
10 mM magnesium chloride 
10 µM tocopherol 
 
PREP2 – 1L 
20 mM MES pH 6.0 
10 mM calcium chloride 
10 mM magnesium chloride 
10 µM tocopherol 
500 mM mannitol 
 
PREP3 – 1L 
20 mM MES pH 6.0 
10 mM calcium chloride 
10 mM magnesium chloride 
10 µM tocopherol 
500 mM mannitol 
20% (v/v) glycerol 
 
PS2LC1 (A0) – 4 L 
20 mM MES pH 6.0 
10 mM calcium chloride 
10 mM magnesium chloride 
10 µM tocopherol 
20% (v/v) glycerol 
0.02% β-DDM 
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PS2LC2 (A150) – 2L 
20 mM MES pH 6.0 
10 mM calcium chloride 
10 mM magnesium chloride 
10 µM tocopherol 
20% (v/v) glycerol 
0.02% β-DDM 
150 mM magnesium sulfate 
 
PMSF stock (made on the day of the experiment) 
0.5 M PMSF in DMSO – 10 mL 
 
Buffer C 
100 mM PIPES-NaOH pH 7.0 
5 mM calcium chloride 
0.03% (w/w) β-DDM 
 
Buffer D0 
100 mM PIPES-NaOH pH 7.0 
5 mM calcium chloride 
 
Buffer D20 
100 mM PIPES-NaOH pH 7.0 
5 mM calcium chloride 
20% PEG-2000 
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4.2. TETRAHEDRA PREPARATION AND PURIFICATION 
4.2.1. Oligonucleotide Design – 20T Tetrahedron 
For the 20T tetrahedron, four single-stranded DNA oligonucleotides each 
63 bases in length were purchased. (Integrated DNA Technologies, Coralville, 
IA) and purified using 8% denaturing-PAGE. See the figure below for a detailed 
dispay of the single-stranded oligonucleotides. The four strands were designed to 
hybridize to other regions of the complementary strands to form the double-
stranded DNA (dsDNA) tetrahedron, consisting of six 20 base pair (bp) edges 
with four apexes containing a single adenine residue. This design was first 
described by Turberfield, et al. [29] 
 
20T Tetrahedron 
 
 
 
 
S1 – AGGCAGTTGAGACGAACATTCCTAAGTCTGAAATTTATCACCCGCCATAGTAGACGTATCACC 
 
S2 – CTTGCTACACGATTCAGACTTAGGAATGTTCGACATGCGAGGGTCCAATACCGACGATTACAG 
 
S3 – GGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCCACTACTATGGCG 
 
S4 – CCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCGACGGTATTGGAC 
 
Figure 4.3. 20T tetrahedron sequences. Each color represents one edge of the 
tetrahedron, 20bp long. Figure taken from reference [29]. 
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4.2.2. Oligonucleotide Design – 30T Tetrahedron 
In order to assemble a 30T tetrahedron which would provide more space 
for molecules to be incorporated, four single-stranded DNA oligonucleotides, 
each 93 bases in length were ordered. (Integrated DNA Technologies, Coralville, 
IA) Figure 4.4 below shows the sequences. 10 extra bases were added to expand 
the size of the tetrahedron, with the goal of making a larger cage and maintaining 
the same G-C content in the structure as in the 20T tetrahedron. This  designed 
tetrahedron structure should assemble into a larger tetrahedron consisting of six 
30 bp edges with four apexes containing a single adenine residue. This structure 
was designed to encapsulate even larger proteins and macromolecules and 
possessed an internal cavity diameter of approximately 100Å.  
30T Tetrahedron 
S1 - 
AGGCAGTTGAGACGAACATTCCTAAGTCTGAATTAGCATAACATTTATCACCCGCCATAGTAGCCATAAGTCCATATCAGCA
TTCGTATCACC 
S2 - 
CTTGCTACACGATTCAGACTTAGGAATGTTCGAATCGTATTGACATGCGAGGGTCCAATACCGTTACGATGCAAGCTTAGCT
ATCGATTACAG 
S3 - 
GGTGATAAAACGTGTAGCAAGCTGTAATCGATAGCTAAGCACGGGAAGAGCATGCCCATCCGGATTCAATAAGGACTTATGG
CTACTATGGCG 
S4 – 
CCTCGCATGACTCAACTGCCTGGTGATACGAATGCTGATAAGGATGGGCATGCTCTTCCCGCCTAAGTTATATGCATCGTAA
CGGTATTGGAC 
 
Figure 4.4. Sequences for the 30T tetrahedron. Image taken from reference [29] 
and adapted for use with the new sequences. The 30T has 10 extra bp on each 
edge, providing a larger cavity for the encapsulation of other molecules.   
 
4.2.3. Purification of Single-Stranded Oligonucleotides 
In order to verify that the oligonucleotide strands were purified, the 
amount equal to 4 O.D. at 260 nm of each strand were loaded in each lane (a 
volume of 16 µL) of a 8% polyacrylamide gel, after mixing with 1X denaturing 
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tracking dye containing 0.1% bromophenol blue in 90% formamide in water and 
heating for 5 minutes at 90 ºC. The ssDNA was run for 2 hours at a current of 45 
mA (per gel) at 37°C and the band containing the monomer of ssDNA was 
extracted from the gel. Further detail on the DNA extraction is described later in 
the Materials and Methods. 
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BUFFERS AND SOLUTIONS USED FOR DENATURING 
POLYACRYLAMIDE GEL ELECTROPHORESIS (d-PAGE) 
0% and 20% PAGE buffers were mixed accordingly to produce the desired 
concentration of polyacrylamide. In most cases, 8% polyacrylamide was used for 
the separation of single-stranded oligonucleotides. In order to achieve 8% PAGE, 
42 mL of 0% PAGE was mixed with 28 mL of 20% PAGE, which made two gels. 
The gels were each 18 x 16 cm and 1.5 mm thick. To polymerize the gels, 525 µL 
of 10% ammonium persulfate (APS) stock solution was added, as well as 30 µL 
of N,N,N’,N’-tetramethylethylenediamine (TEMED). The gel was poured and 
polymerized in 30 minutes. The gel electrophoresis was performed using a SE 
600 Ruby (Amersham Biosciences, Piscataway, NJ, USA). 
 
10X TBE (Tris borate EDTA) – 1000 mL 
108 g Tris base (0.89 M) 
55 g boric acid (0.89 M) 
40 mL 0.5 M EDTA•Na2 pH 8.0 (20 mM) 
fill with diH2O 
 
1X TBE  
100 mL 10X TBE 
900 mL diH2O 
 
0% PAGE – 1000 mL 
500 g urea (8.3 M) 
100 mL 10X TBE 
fill with diH2O 
 
20% PAGE – 1000 mL 
500 g urea (8.3 M) 
100 mL 10X TBE 
500 mL 40% acrylamide stock (19:1 bis:acrylamide) 
fill with diH2O 
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Elution Buffer – 500 mL 
19.27 g ammonium acetate (500 mM) 
1.07 g magnesium acetate (10 mM) 
2 mL 0.5 M EDTA pH 8.0 (2 mM) 
fill with diH2O 
 
1X Denaturing Tracking Dye (Bromophenol Blue) – 100 mL 
90 mL formamide (90%) 
40 mg NaOH (10 mM) 
37 mg EDTA•Na2 (1 mM)  
0.10 g bromophenol blue (0.1%) 
 
1X Denaturing Tracking Dye (Xylene Cyanol FF) – 100 mL 
90 mL formamide (90%) 
40 mg NaOH (10 mM) 
37 mg EDTA•Na2 (1 mM) 
0.10 g xylene cyanol FF (0.1%) 
 
10% Ammonium Persulfate (APS) stock 
1 g ammonium persulfate (10%) 
fill up to 10 mL with diH2O 
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The gel was removed from the electrophoresis chamber and stained with 
ethidium bromide (EtBr) for 5 minutes and then destained in water for 5 minutes. 
Visualization of the bands was done using a UV transilluminator (UVP, Upland, 
CA, USA) set at a wavelength of 302 nm to visualize EtBr. The bands were 
excised from the gel and placed into 0.45 µm filtered Spin-X columns (Corning, 
Lowell, MA) with 0.5 mL of gel elution buffer (500 mM ammonium acetate, 10 
mM magnesium acetate, and 2 mM EDTA•Na2 pH 8.0). The filter trapped the gel 
pieces from eluting along with the DNA. The DNA was extracted from the gel 
matrix at room temperature using a shaker for 1-2 hours before samples were 
centrifuged at 8000 rpm for 6 minutes. The top of the Spin-X column containing 
the gel pieces was discarded and 1 mL of 1-butanol was added to the liquid 
remaining in the bottom of the column, which resulted in the formation of an 
aqueous layer at the bottom (containing the DNA, and an organic layer containing 
ethidium bromide and gel tracking dyes). Samples were centrifuged at 2000 rpm 
for one minute, and the upper organic layer containing ethidium bromide and 
loading dyes was discarded. 1 mL of 100% ethanol was added to the remaining 
DNA and placed in the freezer at -20°C for 2 hours, to precipitate the DNA. 
Samples were centrifuged at 13,000 rpm for 30 minutes at 4°C. The ethanol 
served as an additional precipitation step to ensure purity of the DNA. A white 
pellet was obtained and after removing the ethanol supernatant; another 
precipitation followed, consisting of 70% ethanol. The samples were centrifuged 
at 13,000 rpm for 10 minutes at 4°C, the ethanol supernatant was discarded and 
the pellet was allowed to dry in a vacuum centrifuge for 2 hours with the 
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temperature set to 30°C. After drying the DNA, 50 uL of nanopure water was 
added to each of the tubes and the pellet was resuspended. The ssDNA was 
quantified by measuring the absorbance at 260 nm.  
 
4.2.4. Annealing of 20T Tetrahedron 
The 20T DNA tetrahedron structure was assembled by annealing of 4 
ssDNA strands. Equimolar concentrations of each strand were added to 45 mL of 
annealing buffer [1X TAE-Mg2+ (40 mM Tris base, 20 mM acetic acid, 2 mM 
sodium EDTA, 12.5 mM magnesium acetate)] in 50 mL Falcon tubes (BD, 
Franklin Lakes, NJ) to give a final concentration of approximately 50 nM of DNA 
per tube. Different annealing conditions were initially tested, using concentrations 
between 50 nM and 5 µM. The tubes were placed in a 90°C water bath and cooled 
to room temperature in 2 hours. Following the annealing step at low 
concentrations of DNA, the samples were concentrated in increments of 4 minutes 
at 4000 rpm at 4°C using 30,000 MWCO ultrafiltration devices (Millipore, 
Billerica, MA).  
 
4.2.5. Purification of 20T Tetrahedron 
The purification method used for the 20T tetrahedron was size-exclusion 
chromatography (SEC) using a high pressure liquid chromatography (HPLC) 
instrument. SEC provided a route for selectively isolating the monomeric 
tetrahedron from the aggregation products and low molecular weight DNA 
fragments. The DNA was concentrated to approximately 0.5 mL before loading 
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the sample onto a Superdex SD200 16/60 prep-grade size-exclusion column with 
a 120 mL volume (GE Healthcare, Piscataway, NJ). The tetrahedron was purified 
in 120 mL of 1X TAE-Mg2+ buffer pH 8.0 at room temperature. The tetrahedron 
eluted after approximately 65 minutes at a flow rate of 1 mL min-1.  
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BUFFERS FOR PURIFICATION OF TETRAHEDRON USING SIZE-
EXCLUSION CHROMATOGRAPHY 
 
50X TAE (Tris-acetate EDTA) – 1000 mL 
242.2 g Tris base (2 M) 
57.1 mL glacial acetic acid (1 M) 
37.2 g EDTA•Na2•12H2O (0.1 M) 
fill with diH2O 
 
10X TAE-Mg2+ - 1000 mL 
200 mL 50X TAE (0.4 M) 
26.8 magnesium acetate tetrahydrate (125 mM) 
fill with diH2O 
 
1X TAE-Mg2+ - 1000 mL 
100 mL 10X TAE-Mg2+ 
900 mL diH2O 
 
1X TAE-Mg2+ was the buffer used for all of the column runs for the 20T 
tetrahedron. The 50X and 10X were stock solutions. 
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4.2.6. Concentrating the Tetrahedron 
The samples were collected and concentrated to at least 1.5 mg DNA ml-1  
or 12 µM for crystallization experiments. The concentration step was performed 
using 30 000 molecular weight cut-off (MWCO) filters (Millipore, Billerica, MA, 
USA) which also removed traces of contaminants formed in the annealing 
process. Typical concentrations ranged from 1-4 mg ml-1 or 10-40 µM for 
crystallization and other further experiments.  
 
4.3 CHARACTERIZATION OF 20T TETRAHEDRON 
4.3.1. Quantification using UV-Vis 
Following purification using SEC, the tetrahedron was concentrated to 
approximately 1-4 mg ml-1 or 10-40 µM. The concentration was verified by 
measuring the absorbance at 260 nm using a Quartz 10mm cuvette. A dilution 
factor of 100 was used in preparing the samples for UV/Vis analysis. 1µL of 20T 
was mixed with 99 µL of 1X TAE-Mg2+. The concentration of dsDNA was given 
in the range of 6-40 µg ml-1 and this was converted to mg ml-1 with the 100X 
dilution factor included.   
 
Using the calculated extinction coefficient for the 20T: ε = 2,109,396 M-1 cm-1 
(calculated using the online calculator from Integrated DNA Technologies, 
Coralville, IA) and the equation below, the molar concentration was calculated.  
A260 = ε * [c] * d (pathlength was 1 cm)  
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4.3.2. Native Gel Electrophoresis 
Prior to crystallization experiments, native gel electrophoresis was used to 
analyze the homogeneity of the 20T tetrahedron. Samples were prepared for 
native gel electrophoresis by mixing the 20T tetrahedron at a concentration of 2 
mg ml-1 with 10X native tracking dye [0.2% (w/v) bromophenol blue, 0.2% (w/v) 
xylene cyanol, and 50% glycerol in 1X TAE-Mg2+]. Samples were run on a 5% 
polyacrylamide native gel for approximately 3 hours at 20°C. Unpurified and 
purified tetrahedron samples were both analyzed using native gel electrophoresis. 
Samples were prepared for native gel electrophoresis by mixing 20T at a 
concentration of 2 mg ml-1 with 10X native tracking dye.  
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BUFFERS USED FOR NATIVE GEL ELECTROPHORESIS OF 
TETRAHEDRON 
50X TAE (Tris-acetate EDTA) – 1000 mL 
242.2 g Tris base (2 M) 
57.1 mL glacial acetic acid (1 M) 
37.2 g EDTA•Na2•12H2O (0.1 M) 
fill with diH2O 
 
10X TAE-Mg2+ - 1000 mL 
200 mL 50X TAE (0.4 M) 
26.8 magnesium acetate tetrahydrate (125 mM) 
fill with diH2O 
 
10X Native Tracking Dye – 100 mL 
0.2 g bromophenol blue (0.2%) 
0.2 g xylene cyanol FF (0.2%) 
50 mL glycerol (50%) 
10 mL 10X TAE-Mg2+ (1X) 
40 mL diH2O 
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4.3.3. Dynamic Light Scattering (DLS)     
Prior to crystallization experiments, Dynamic Light Scattering (DLS) 
(Molecular Dimensions, Apopka, FL, USA) was also used to analyze the 
homogeneity of the 20T tetrahedron. Samples were prepared for DLS by placing 
3 µL of 20T (concentration 2 mg ml-1) in the center of a siliconized cover slide, 
inverting and placing on the top of a well containing 0.9 mL of the buffer solution 
(1X TAE-Mg2+ pH 8.0). A 60 mW 785 nm laser was aligned with the detection 
channel to  the drop so that they interact, and data was collected at 20 second 
intervals 10 times. Parameters for the DLS instrument were adjusted for the 20T 
to account for its lower density compared to that of proteins, and the resulting 
hydrodynamic radius distribution was observed. The parameters used were the 
following: concentration 1, refractive index 1, shape factor 1, hydration shell 0.2, 
exponent 2.3 (a calculation which would provide the molecular weight given the 
size of the molecule), and molecular density 0.4. The fraction of single 
tetrahedrons vs aggregates were calculated by integration of the peaks and divided 
by scattering intensity increases by r6. The amount of aggregates was calculated 
by dividing the peak integration area by radius6.  
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4.4 CRYSTALLIZATION OF 20T TETRAHEDRON 
4.4.1. Crystallization of Tetrahedron 
Immediately following annealing and purification, crystallization experiments 
were conducted. Initial crystallization experiments of the 20T tetrahedron resulted 
in small crystals in different conditions of the Sigma Nucleic Acids screen. Initial 
screening indicated crystallites in the following conditions:  
• 50 mM cacodylate pH 6.0, 20 mM argininamide, 1 mM barium chloride, 2 
mM spermidine hydrochloride, 30% PEG 400 
• 50 mM HEPES pH 7.0, 1 mM cobalthexamine chloride, 35% PEG 400 
• 50 mM cacodylate pH 6.5, 20 mM lithium chloride, 5 mM cobalt (II) 
chloride, 35% PEG 600 
• 50 mM HEPES pH 7.0, 20 mM ammonium chloride, 5 mM MgCl2, 35% 
PEG 600 
• 1 mM cobalthexamine chloride, 2 mM putrescin hydrochloride, 35% PEG 
600 
• 50 mM cacodylate pH 6.0, 20 mM argininamide, 1 mM cadmium 
chloride, 30% PEG 1000 
 
The tetrahedron was concentrated to a range of concentrations (1.5 mg ml-1 – 4 
mg ml-1). 2.5 mg ml-1 was the average concentration used for both the 
crystallization and DLS experiments. Sparse matrix screens (Sigma, St. Louis, 
MO) were initially used in determining the initial condition for the crystallization 
of the tetrahedron. Crystallization was further optimized to 29-34% PEG-1000, 
10-25 mM L-argininamide, and 50 mM sodium cacodylate pH 6.0. A 24-well 
plate hanging drop setup was used (Qiagen, Valencia, CA) for all crystallization 
optimization experiments. 1 µL of tetrahedron was mixed with 1 µL of screen 
solution and placed on the cap. 0.9 mL of screen solution was placed in the 
reservoir. Crystals were grown in an incubator at 23°C and formed in 
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approximately 2-3 days. Optimization experiments included varying several 
parameters including varying the concentration of the tetrahedron (1-4 mg ml-1), 
salt concentration, precipitant concentration, additives, pH variation, and 
temperature to achieve better quality crystals. In an attempt to grow larger 
tetrahedron crystals, heterogeneous nucleation experiments were performed using 
human hair as the nucleation agent.  
 
All Screen Solution materials and concentrations are found in the 
Appendix Section. 20T fine screens 1 and 2 were designed based on prior results 
obtained from the Sigma Nucleic Acid Screen which gave the best “hits” for 
crystals with the screen solution named “H11”. Screens 1 and 2 ranged from 23-
38% PEG-1000 and 10-25mM L-argininamide.  20T Fine Screen 4 was used as a 
fine-tuned version of 20T Fine Screens 1-3, after determining that the best 
crystals grew in the 28-34% PEG-1000 range.  
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4.5 CRYSTAL FREEZING AND CRYOPROTECTANT MATERIALS 
Freshly grown tetrahedron crystals were incubated in a range of 
cryoprotectants before being frozen in liquid nitrogen. Several tests were 
conducted in order to establish the best cryoprotectant for the 20T tetrahedron 
crystals and thus eliminate the formation of ice rings in the x-ray diffraction 
experiments. The Nextal Cryos Suite screen kit was used (Qiagen, Valencia, CA) 
for the initial cryo-cooling experiments. Crystals were first transferred into the 
various cryoprotectants which contained potential cryo-preservatives such as 2-
methyl-1,3-propanediol (MPD), isopropanol, glycerol, sucrose, various PEGs, and 
different buffers including Tris, HEPES, PIPES, and MES. The idea behind the 
screen is to quickly replace the water by the cryo-protectant. However, in all of 
those cryoprotectant screen solutions, the tetrahedron crystals dissolved 
immediately. Therefore, an optimized cryoprotectant was developed that 
contained 40% PEG-1000, 60 mM sodium cacodylate pH 6.0, and 18 mM L-
argininamide (a variant of the screen solution in which the crystals grew). Other 
cryoprotectant solutions included 50% PEG-2000, 60 mM sodium cacodylate pH 
6.0, and 18 mM L-argininamide, in which the crystals remained stable as well. 
Crystals were incubated for approximately 10 -30 minutes before being flash-
frozen in liquid nitrogen, in order to prevent the formation of ice rings in 
diffraction patterns.  
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4.6 X-RAY DATA COLLECTION 
X-ray diffraction experiments were conducted at Lawrence Berkeley 
National Laboratory at the Advanced Light Source Beamline 4.2.2 and 8.2.2 and 
Argonne National Laboratory at the Advanced Photon Source at beamline ID-19. 
The wavelength of the x-ray beam was 1 Å, photon flux was 1012 photons sec -1 
and the beam size was 150 x 200 µm and exposure time was an average of 3 
seconds. The crystals were rotated 200° and the oscillation range was 1° per 
image. The crystals were aligned in a cryostream of liquid nitrogen at a distance 
of 500 mm from the detector, and the detector size was 3072 x 3072 pixels.   
 
4.7. IMPROVING CRYSTAL QUALITY AND ANALYSIS OF 
TETRAHEDRON STABILITY 
4.7.1. Improving crystal quality by varying pH in screen solutions 
In order to improve crystal quality and diffraction quality, tetrahedron 
crystals were successfully produced in screen solutions that contained different 
buffer systems such as Tris, Tris + cacodylate, and MES. Six screen solutions 
were developed with pH varying between 6.0-9.0, but containing the same salt 
(argininamide) and precipitant (PEG-1000) as the original screening conditions 
20T Fine Screens 1-4. However, the PEG-1000 concentration was lowered in 
order to grow larger crystals at a slower rate.  
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4.7.2. Changing counterions in screen solutions and omitting argininamide 
Another set of screens was designed in order to improve crystal diffraction 
quality and overall DNA stability. The screen solutions used additives of 
magnesium acetate in order to introduce more divalent cations into the 
crystallization conditions to stabilize the DNA phosphate backbone during the 
crystallization process. Different buffers were used as well, instead of only 
sodium cacodylate pH 6.0. Crystallization experiments were set up as previously 
described for original screening conditions. 
 
4.7.3. Changing the magnesium counter-anions  
Another set of screens was designed in order to test the influence of the 
concentrations of magnesium sulfate on the crystal formation and overall DNA 
stability. The screen solutions used counter-anions of magnesium (magnesium 
sulfate) in the crystallization conditions, as designed in Screens 8-10 except in 
some cases argininamide was omitted, and magnesium acetate was omitted and 
replaced with magnesium sulfate. Crystallization experiments were set up as 
previously described for original screening conditions. All crystallization screen 
charts are shown in the Appendix.  
 
 
 
4.7.4. 20T tetrahedron crystal dehydration 
20T crystals were dehydrated as another attempt to improve their 
diffraction quality. 20T tetrahedron crystals grown in 32% PEG-1000, 10mM 
argininamide, and 50mM sodium cacodylate pH 6.0 were transferred to the post 
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of a sitting drop tray with 10 µL of the screen solution containing 35% PEG-1000, 
10mM argininamide, and 50mM sodium cacodylate pH 6.0., and 1000 µL of 50% 
PEG-1000, 10mM argininamide, and 50mM sodium cacodylate was added to the 
reservoir. The setup is described in Figure 5.11 in the Results section. 
 
4.7.5. Analysis of tetrahedron stability following x-ray exposure 
To test the stability of the DNA following exposure to synchrotron 
radiation, freshly dissolved 20T crystals used for data collection were 
immediately dissolved directly from the cryoloop in 1 µL 10X native tracking dye 
containing bromophenol blue and xylene cyanol before they were loaded onto an 
5% native polyacrylamide gel. The samples were run for approximately two hours 
at 45 mA at 20° C.  
 
 
 
 
 
 
 
 
 
 
 
  68 
4.8 NUCLEOTIDE-PEPTIDE CONJUGATION METHODS 
4.8.1 PSII PEPTIDES – TOWARDS BUILDING THE aOEC  
 
PSII peptide synthesis 
According to the proposed design of the artificial oxygen-evolving 
complex (aOEC), three peptide sequences were developed based on the natural 
protein sequence of different subunits of the PSII reaction center that are 
responsible for coordinating the 4MnCa cluster. The first peptide sequence that 
has been synthesized is a modified mimic of the C terminus of D1 of PSII. The 
peptide is 35 aa in length. A 7-aa linker consisting of multiple glycines and 
tryptophans was included in the sequence to facilitate flexibility at the N-terminus 
(glycines) and to facilitate the use of fluorescence microscopy on conjugate 
crystals (tryptophan fluorescence).  The peptide sequence is shown below and it 
was synthesized C to N terminus using a microwave peptide synthesizer (CEM, 
Matthews, NC) in the presence of β-maleimidipropionic acid and with 9-
fluorenylmethyloxycarbonyl (F-moc) as the protecting group. The deprotection 
consisted of 20% piperidine in dimethylformamide (DMF), which provided the 
mild, basic conditions necessary for successful cleavage of the F-moc protecting 
group. Following cleavage from the resin (Wang resin), the peptide was N-
terminal functionalized with a maleimide group for conjugation purposes. The 
functional groups (for the conjugation step) as well as the critical parts of the 
peptide are shown in Figure 5.21 in the results section. The highlighted portion of 
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the peptide sequence below indicates the linker designed to provide flexibility and 
tryptophan residues for use in tryptophan fluorescence experiments. 
 
H3N+ - G W G G W G G A D I I N R A N L G M N E V M H E R N A H N F P L D L A - COO- 
 
The peptide was purified using reverse-phase chromatography in a gradient from 
0-100% acetonitrile in water, and 0.1% trifluoroacetic acid (TFA) on a C4 reverse 
phase column (Waters, Milford, MA). 
 
Secondary Structure Determination of PSII Peptide by Circular Dichroism 
In order to test the presence of either alpha helices or beta sheets in the 
synthesized peptide, Circular Dichroism (CD) was used. To prepare samples for 
CD, 1 mg ml -1 of peptide was placed in a Quartz cuvette and the samples were 
measured with a wavelength scan from 180 – 280 nm. No temperature gradient 
was used for these experiments – they were conducted at room temperature. 
Several wavelength scans were repeated in order to observe the secondary 
structure.  
 
Manganese (II) titration of PSII Peptide 
In a different set of tests, the peptide was titrated with concentrations of 
manganese (II) sulfate (manganese (II) chloride absorbs in the UV region and 
would interfere with measurements), even though binding would mainly be 
expected in the oxidation states of Mn(III) and Mn(IV). Different concentrations 
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ranging from 10-50 mM of manganese (II) sulfate were added to the peptide to 
detect if a conformational change in the peptide upon metal binding can be 
observed. Again, multiple wavelength scans from 180 – 280 nm were compiled 
and analyzed.  
 
PSII peptide conjugation 
The CT-D1 peptide was coupled to one specific site on the ssDNA (strand 
4 of tetrahedron strand). One thymine was chemically modified with a thiol linker 
to facilitate coupling to the peptide via the N-terminal maleimide group. In the 
presence of tris(2-carboxyethyl)phosphine (TCEP), the ssDNA with the thiol 
linker was reduced to allow the free thiol to be exposed. The DNA sample was 
added to a spin column (Pierce, Rockford, IL, USA) in the presence of TCEP (to 
prevent the formation of disulfide bonds between thiolated DNA strands) and 
centrifuged for 2 minutes at 1500 x g with the 50-fold excess peptide (similar to 
the procedure described in [57]) solution in the bottom of the tube to allow the 
reaction to occur immediately between the peptide-DNA, reducing the possibility 
of accumulating ssDNA dimers. Figure 4.6 shows a schematic picture of the 
conjugation and is shown below. The sequences for the single peptide conjugation 
site construct of the tetrahedron are shown below. 
 
 
S1 - AGGCAGTTGAGACGAACATTCCTAAGTCTGAAATTTATCACCCGCCATAGTAGACGTATCACC 
S2 - CTTGCTACACGATTCAGACTTAGGAATGTTCGACATGCGAGGGTCCAATACCGACGATTACAG 
S3 - GGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCCACTACTATGGCG 
S4 – /5ThioMC6-D/ACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCGACGGTATTGG 
Figure 4.5. Sequences for the single conjugation site on the DNA strand 4 
containing the thiolated thymine. Sequences and associated colors adapted from 
reference [29]. 
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Figure 4.6. Conjuation scheme for the CT-D1 peptide and the 5'-thiol modified 
DNA strand 4.  
 
PSII peptide annealing 
Two strategies were employed regarding coupling of ssDNA to the 
peptide sequence. In one strategy, the peptide was coupled to the ssDNA first, in 
the scheme shown in Figure 4.6, and then the strands were annealed in equimolar 
concentrations at 90ºC to form the tetrahedron. In the second strategy, the 
tetrahedron with the thiol modified strand was annealed first, and the peptide was 
coupled later in the presence of the reducing agent in 1X TAE-Mg2+. In both 
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cases, the construct was purified using size-exclusion chromatography, and the 
sample was concentrated to 2 mg ml-1 for further experiments.  
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4.8.2. INCORPORATION OF PEPTIDE-BOUND PORPHYRINS INSIDE OF 
THE TETRAHEDRON 
Tetrahedron-Porphyrin-Binding Peptides Conjugation 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Schematic drawing of the experimental design for the porphyrin 
coordination inside of the tetrahedron - Scheme 1 indicates the method used to 
assemble the DNA framework first and later incorporate the porphyrin, while 
Scheme 2 requires porphyrin coupling first, and then annealing later. 
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Figure 4.8. Schematic for oligonucleotide-peptide conjugation mediated by 
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC). 
Conjugation scheme adapted from reference [58] 
 
As a proof of concept that metal-containing molecules can be incorporated 
inside of the tetrahedron, a water-soluble iron(III) porphyrin (Frontier Scientific, 
Logan, UT, USA) was introduced via two short peptide sequences containing 
terminal histidine residues that would axially coordinate to the iron(III) center of 
the porphyrin. The peptide sequence selected was CAGAGSWH (synthesis 
performed by Genscript, Piscataway, NJ, USA). The peptides were first 
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covalently attached to a ssDNA strand (strand 4) which had two amine-modified 
thymines that would be conjugated to the cysteine sulfur via heterobifunctional 
crosslinker SMCC. The nucleotide sites were selected based on how the 
tetrahedron folds to make sure that the peptides would reside inside the DNA 
tetrahedron. One of the conjugation sites had been successful for incorporating the 
CT-D1 peptide described earlier in this work. The other site was selected based on 
the folding of the tetrahedron (that site should be facing the inner cavity of the 
tetrahedron). There were two schemes for porphyrin incorporation shown in 
Figure 4.7 - one was to first assemble the tetrahedron with the peptides already 
attached and then add the porphyrin into the solution, and the other was to first 
couple the porphyrin to the ssDNA strand 4 with the peptides already covalently 
attached and then anneal all strands together.  
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Figure 4.9. Flowchart describing experimental details of ssDNA-peptide 
conjugation leading to porphyrin assembly inside of the tetrahedron, using the 
procedure outlined in Figure 4.7 Scheme 1. 
 
 
ssDNA-SMCC coupling 
 For DNA-SMCC conjugation, 84 µM of 20T amine-modified strand 4 was 
used. 50 µL of this sample was taken and added to 50 µL of 1X PBS (pH 7.3). 
The final concentration of ssDNA strand 4 was 42 µM. Next, a 2 mg ml-1 solution 
of (Succinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate) (SMCC) 
(Sigma, St. Louis, MO) in acetonitrile was made by dissolving 2 mg of SMCC in 
1 mL of acetonitrile at room temperature. The final concentration of SMCC was 
approximately 4 mM. It is necessary to have at least a 50-fold excess of SMCCfor 
the reaction to take place. 500 µL of 2 mg/ml (4 mM) SMCC was added to 100 
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µL of 42 µM S4 in 1X PBS pH 7.3. The reaction took place for 3 hours at room 
temperature. In order to precipitate the DNA and isolate it from the excess 
SMCC, 20µL of Elution Buffer (same buffer used for ssDNA extraction from gel 
matrix – see Buffer List), and 800 µL 100% ethanol were added to a 1.5 mL 
reaction vessel and placed in the -20°C freezer for at least 2 hours (overnight was 
preferable). The sample was centrifuged at 13,000 rpm for 30 min at 4°C. A white 
pellet was observed following centrifugation. The supernatant was discarded, and 
800 µL 70% ethanol was added to the pellet. The sample was centrifuged at 
13,000 rpm for 10 min at 4°C. The ethanol was discarded and the tube was placed 
in a vacuum centrifuge for 1.5 hours with the temperature set to 30°C. A dry 
pellet was obtained after the ethanol evaporated, and the pellet was stored at -
20°C. The conjugate is stable at -20°C in pellet form for up to one month; 
however, the sample can also be immediately used for a reaction with short 
peptide sequences. In order to characterize the mass of the desired product, 
MALDI-TOF and denaturing-PAGE were used. Samples were prepared for 
MALDI-TOF by resuspending the pellet in 50 µL H2O. A small amount of dried 
Dowex was added to the sample and mixed thoroughly to remove salt from the 
sample. The resin removes excess salts so they do not interfere with the 
measurements, which is a common problem when working with nucleic acids. 
[59] 
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ssDNA-SMCC-peptide conjugation and characterization by MALDI-TOF  and 
PAGE 
 A stock solution of 4 mg/ml of peptide (3.2 mM) was prepared by weighing 
4 mg of 8aa peptide CAGAGSWH (called “P8”) and dissolving in 1 mL of 1X 
PBS pH 7.3. The concentration of the SMCC-conjugated 20T strand 4 was 84µM. 
A 50-fold excess was necessary for the coupling of peptide to ssDNA-SMCC. 250 
µL of 20T S4 was mixed with 500 µL of peptide stock solution and incubated for 
at least 3 hours at RT. To remove excess peptide, NAP-5 gravity flow size-
exclusion columns were used. (GE Healthcare, Piscataway, NJ) The NAP-5 
column was equilibrated with 3 column volumes of 1X PBS pH 7.3 for a total 
volume of 9 mL. Following column equilibration, the sample containing the 
DNA-peptide conjugate was applied to the column and eluted with 3 column 
volumes of buffer. The fractions were collected, and the sample was applied to a 
10 000 MWCO filter (Millipore, Billerica, MA, USA) and concentrated. A 
concentration of 80 µM and volume of approximately 200 µL was achieved 
following concentration. The sample was characterized using MALDI-TOF, 
which showed a clear peak representing the expected mass of the conjugate at 
21.2 kDa. Samples for MALDI-TOF were prepared by mixing the purified 
conjugate with matrix (saturated 3-hydroxypiccolinic acid solution) in a 1:1 ratio, 
and then adding solid Dowex resin to the sample to remove salt. 1 µL spots were 
placed on the MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time 
of Flight) sample plate and dried before analysis. Additionally, the conjugate was 
characterized using 10% denaturing-PAGE gel shift assays, which showed an 
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approximate shift of 1.5 kDa between the purified 20T S4 and purified 20T S4-
peptide conjugate at the same concentration. (See Figure 5.30 in the Results.) For 
the denaturing gel shift assay, 10 µL of sample (both the S4 and conjugated S4) 
was mixed with 10 µL 2X denaturing tracking dye containing bromophenol blue, 
vortexed for 10 seconds, centriguged at 2000 rpm for 30 seconds, and then heated 
for 5 minutes at 90°C. Then the samples were applied to the 10% denaturing-
PAGE gel and ran for 1 hour 20 minutes at 35°C. The gels were stained using 
ethidium bromide, destained, and visualized on a UVP Biospectrum Imaging 
System at 302 nm.  
 
Annealing of Strand 4-P8 Conjugate with 20T S1-S3 
80 µM of purified S4 conjugate was mixed with the other strands 1-3 of 
the tetrahedron in equimolar ratios. The samples were annealed in 50 nM 
concentrations in 1X TAE-Mg2+ concentrated to approximately 1 mL, and 
subsequently purified using SEC. The samples were applied to a Superdex 200 
prep-grade column (GE Healthcare, Piscataway, NJ) and a flow rate of 1 ml min-1 
was used. The chromatogram verifies that the 20T-peptide complex (20TP8) 
eluted at approximately the same time as the 20T. Wavelengths of 260 and 280 
nm were used to measure both DNA and peptide.  
 
Peptide-porphyrin sample preparation : UV-Vis and EPR 
As a preliminary test, just the P8 peptide and Fe(III)-TPPS4 porphyrin were 
mixed in varying concentrations in order to verify the spectroscopic properties of 
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free porphyrin and histidine-coordinated porphyrin. To do this, a 10 mM stock 
solution of peptide and 2 mM stock solution of porphyrin were made. The 
following dilutions were prepared: 
0.5 mM porphyrin 
0.5 mM porphyrin : 0.5 mM peptide 
0.5 mM porphyrin : 1 mM peptide 
0.5 mM porphyrin : 2.5 mM peptide 
0.5 mM porphyrin : 5 mM peptide 
These samples were prepared for EPR and UV-Vis experiments in 1X TAE⋅ or -
Mg2+ with 20% glycerol. A second set of samples with the same dilutions was 
also prepared in the same buffer but without EDTA. EPR tubes (Wilmad 
LabGlass, Vineland, NJ) were loaded with 180 µL of each dilution and frozen in 
liquid nitrogen. A small amount of sample was used for UV-Vis analysis and a 
wavelength scan was performed from 250-800 nm. Continuous wave X-band EPR 
analysis was performed at a temperature of 6 K with a frequency of 9.340 GHz 
and 2 mW power using a Continuous Wave (CW) X band (9-10GHz) Bruker 
ESP300E  spectrometer with an Oxford ESR 900 cryostat (Bruker, Billerica, MA, 
USA).   
 
20T-peptide-porphyrin sample preparation : UV-Vis and EPR 
Following purification of the 20T-peptide construct via size-exclusion 
chromatography, the sample was concentrated to approximately 10 µM. A 1 mM 
stock solution of the porphyrin was made. The buffer condition was 1X TAE-
Mg2+ with 20% glycerol. Another set of EPR samples were prepared – (1) 5 µM 
porphyrin, (2) 5 µM porphyrin + 10 µM peptide (as a control), and (3) 5 µM 
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porphyrin + 10 µM 20T-peptide, 100 µL total volume per sample. Continuous 
wave X-band EPR analysis was performed using a temperature of 6K, 9.340 GHz 
frequency, and 2 mW power. Samples were also analyzed using UV-Vis and were 
prepared by adding 20 µL of the samples to a Quartz 10mm cuvette and 
performing a wavelength scan from 250-800 nm.  
 
Native gel electrophoresis   
 The 20T-peptide-porphyrin complex was analyzed for the presence of 
monomer and aggregates using the same dilutions as mentioned in the EPR 
experiments. 18 µL of 10 µM 20T-peptide was mixed with 2 µL of 10X native 
tracking dye containing bromophenol blue and xylene cyanol and loaded onto a 
5% native polyacrylamide gel. 18 µL of 10 µM 20T-peptide : 5 µM porphyrin 
dilution was mixed with 2 µL of native tracking dye and also loaded onto the gel. 
Samples were run at 90 mA at 20 °C for approximately 4 hours. The gel was 
stained in ethidium bromide, destained in water, and illuminated at 302 nm and 
visualized using a camera (UVP, Upland, CA).  
 
Dynamic Light Scattering Measurements 
As another test to analyze if aggregates formed through the addition of 
porphyrin, DLS samples were prepared.  A freshly prepared 60 µL aliquot of 10 
µM 20T-peptide sample was placed in a cuvette and transferred into the light 
scattering instrument (Wyatt, Santa Barbara, CA, USA) and 20 measurements 
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were taken in increments of 10 seconds each. The software analyzed each 
measurement and a distribution plot was generated. The same procedure was 
repeated for the 20T-peptide-porphyrin sample. The same concentration was used 
(10 µM) but mixed with porphyrin to achieve a final concentration of 10 µM 20T-
peptide and 5 µM porphyrin. Following DLS analysis, peak integration was 
performed using the accompanying software from Wyatt. A spherical protein was 
assumed as the overall shape for the calculations, since no 3D DNA parameter or 
manual entry of a parameter set was allowed.  
 
Crystallization of 20T-Peptide and 20T-Peptide-Porphyrin 
Solving the structure of the empty 20T tetrahedron has proven 
challenging, and it may be possible that internally assembling peptides and 
porphyrins stabilize the tetrahedron and improve the diffraction quality of the 
crystals. Therefore, crystallization trials  for the 20T tetrahedron-porphyrin were 
set up. First, the 20T-peptide was used and the concentration was 20 µM or 
approximately 2 mg ml-1. For the 20T-peptide-porphyrin, the final concentrations 
were 10 µM 20T-peptide and 5 µM porphyrin. The experiments were set up in 
trays (Qiagen, Valencia, CA) using the vapor diffusion method, using a hanging 
drop set up due to the limited amount of the 20T-peptide and the 20T-peptide-
porphyrin samples. For the hanging drop setup, 1 µL of 20TP8 sample was mixed 
with 1 µL of the screen solution and placed in the center of a glass cover slide. 
This cover slide was placed over the well containing 500 µL of the screen 
solution in the reservoir. This same procedure was repeated when testing the 
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20TP8P samples. A modified 20T Fine Screen 4 was designed, with only 5 
conditions selected from the 24-condition screen. Experiments were set up for 
both the 20T-peptide and the 20T-peptide-porphyrin in order to test whether the 
porphyrin hinders or aids in the crystallization process. The conditions used were 
the following: 
20T Fine Screen 4, condition 3 
31% PEG-1000 
10 mM argininamide 
50 mM sodium cacodylate pH 6.0 
 
condition 9 
31% PEG-1000 
15 mM argnininamide 
50 mM sodium cacodylate pH 6.0 
 
condition 16 
32% PEG-1000 
20 mM argnininamide 
50 mM sodium cacodylate pH 6.0 
 
condition 20 
30% PEG-1000 
25 mM argnininamide 
50 mM sodium cacodylate pH 6.0 
 
condition 24 
34% PEG-1000 
25 mM argininamide 
50 mM sodium cacodylate pH 6.0 
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5. RESULTS AND DISCUSSION 
5.1. PSII RESULTS 
5.1.1. Purification of PSII using AEC 
 Purification of PSII involved the use of AEC. The PSII dimer peak 
typically elutes around 100 minutes into the purification run, at a flow rate of 10 
ml min-1. The peak is shown in Figure 5.1 below.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Purification of PSII using AEC. The PSII dimer peak elutes around 
100 minutes. The peaks around 20-40 minutes are of PSI and other proteins 
isolated from PSII. Chromatogram modified from the original data obtained by 
Chris Kupitz.  
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The PSII crystals typically grew in 1-2 days and had a very solid green 
appearance, usually with a diamond or square shape. The best crystallization 
conditions for PSII were usually in the 2-4% PEG-2000 range, as shown in the 
crystal gallery in Figure 5.2. Many trials of crystallization conditions were 
attempted, including decreasing and increasing the PEG-2000 concentrations; 
however, the highest quality crystals still grew in 2-4% PEG-2000. Increasing the 
PEG-2000 concentration resulted in smaller crystals, as shown in Figure 5.2b.    
  
Figure 5.2. PSII crystal gallery. Figure a shows crystals grown in 4% PEG-2000 
in Buffer C. B shows crystals grown in 4.5% PEG-2000 that are visibly smaller 
than those shown in a. C shows hexagonal shaped crystals grown in 2% PEG-
2000. D shows crystals grown in 2% PEG-2000 in a batch crystallization 
experiment under paraffin oil. These crystals all formed in approximately 1-2 
days. 
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Figure 5.3. Diffraction pattern from a PSII crystal to a resolution limit of 
approximately 4 Å. This diffraction pattern was collected at the Advanced Light 
Source at Lawrence Berkeley National Laboratory. Figure courtesy of Dr. 
Raimund Fromme.   
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5.2. DNA TETRAHEDRON DESIGNS 
 
A schematic view of the tetrahedron constructs  investigated in this study 
is shown in Figure 5.4, which include  a 20T  (20 base pairs on each edge), [29] 
20x30T (asymmetrical with 20 base pairs on each edge for one face and 30 bp on 
each edge for the other faces), [29] and a 30T (30 base pairs on each edge) 
tetrahedron. The size variations were designed to increase the cavity size which 
would in a later stage of the project allow  for the incorporation of larger  proteins 
and macromolecules inside the tetrahedrons. The sequences of all strands for each 
of the three constructs are described in Materials and Methods. While the 20T 
tetrahedron has an estimated inner volume of 32,364 Å3 , the inner volume is 
significantly increased to 58,955 Å3  for the 20x 30 T construct and 125,064 Å3 for 
the 30T tetrahedron. Assuming a sphere fitting inside of each symmetrical 
tetrahedron, it would have a diameter of 70 Å for the 20T and 100 Å  for the 30T 
tetrahedron. The increased size of the larger tetrahedron constructs is confirmed 
by native gel electrophoresis  as shown in  Figure 5.7 c-d.   
 
 
 
 
 
 
Figure 5.4. Dimensions of tetrahedra described in this work. Figure submitted to 
the journal Acta Crystallographica F. October 2012 and is currently under 
review. 
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5.3. TETRAHEDRON ASSEMBLY AND PURIFICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Purification scheme for 20T tetrahedron. The same purification 
procedure was used for other constructs. Both size-exclusion chromatography and 
native gel electrophoresis verified that the aggregates and fragments were isolated 
from the monomeric 20T. This same scheme was used for other constructs as 
well. Figure submitted to the journal Acta Crystallographica F. October 2012 and 
is currently under review. 
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5.3.1. Tetrahedron preparation results 
The 20T tetrahedron was successfully purified using size-exclusion 
chromatography, as shown in Figure 5.5. The figure shows a schematic overview 
of the assembly and purification indicating the annealing of the four single-
stranded DNA oligonucleotides, and the purification via size-exclusion 
chromatography. The purification procedure is verified by native gel 
electrophoresis of the sample before and after size exclusion chromatography (Fig 
5.5 bottom right) which shows that  the aggregates (band "a") and partially 
assembled structures (band "c") are successfully removed from the fully 
assembled tetrahedron monomer (band 'b') by the purification procedure. 80% of 
the DNA could be recovered as monomeric tetrahedron from the SEC column 
runs.    
 
5.4 TETRAHEDRON CHARACTERIZATION 
5.4.1. Analysis of homogeneity of the preparation 
For each construct, the homogeneity of the sample was verified by 
analyzing the sample before and after purification on a 5% native polyacrylamide 
gel. Additionally, DLS was used to demonstrate homogeneity following 
purification, described below in more detail. Table 1 describes the calculations 
used to quantify the amount of aggregation in the sample.     
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5.4.2. Quantification through UV-Vis 
The concentration of the tetrahedron was verified through UV-visible 
spectroscopy by measuring the absorbance of dsDNA at 260 nm using a molar 
extinction coefficient of 2,109,396 M-1 cm-1 (calculated using the online calculator 
from Integrated DNA Technologies, Coralville, IA) Typically, the concentration 
of the obtained sample ranged from 10-40 µM at a volume of 100-200 µL. 
  
5.4.3. Optimization of the annealing step – concentration dependence 
In prior research [29] annealing concentrations of 5 µM or more were used 
to form DNA tetrahedron structures from for the single-stranded DNA 
oligonucleotides. However, at these concentrations, large qualities of aggregates 
are detected by  size-exclusion chromatography and  native gel electrophoresis. 
As aggregation is a concentration dependent process, we tested if we can 
eliminate or reduce the formation of aggregates by varying the annealing 
concentration. During the annealing step, different concentrations of 
oligonucleotides were tested—ranging from 50 nM to 5 µM, and we also explored 
different cooling times. With the variation of the cooling time we wanted to 
explore if aggregate formation can be reduced by slower cooling rates that 
provides more time for the tetrahedron structures to form. The results are shown 
in Figure 5.6 for cooling times of 30 seconds and 90 minutes and DNA 
concentrations of 50nM, 0,2 µM and 0.5µM. The higher concentration during 
annealing of the 20T and 20x30T tetrahedra resulted in a significant amount of 
aggregation, as shown in Figure 5.6, lanes 1 and 3, while significantly lower 
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amounts of aggregates are observed at the 0.2 µM concentration shown in Figure 
5.6a, lanes 2 and 4. Figure 5.6b compares the results for the 50 nM and 0.2µM 
concentrations of DNA. The results shows that aggregates could be further 
reduced for the 20T and 20x30T construct by decrease of the annealing DNA 
concentration to 50nM (compare lanes 3/4 and 7/8 (50nM) to lanes 1/2 and 4/5 
(0.2 µM).  In contrast to the clear concentration dependence, the annealing  time 
had no detectable influence on the formation of aggregates as shown in Fig 5.6b 
where very similar ratios of monomers and aggregates are detected at annealing 
times of 30 seconds (odd numbered lines) and 90 minutes (even-numbered lines 
in Fig 5.6b).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Concentration and time dependence studies during the annealing step 
of 20T and 20x30T constructs. The samples shown in (a) in Lanes 1 and 3 were 
annealed at a concentration of 5 µM which resulted in more aggregation than in 
Lanes 2 and 4 which were annealed in 0.2 µM. The gel in (b) shows even lower 
 
  92 
annealing concentration comparisons. Lanes 1-2 and 5-6 were annealed at 0.2 µM 
and had more aggregation. Lanes 3-4 and 7-8 were annealed at a concentration of 
50 nM and resulted in the least amount of aggregates. In (b), Lanes 1,3,5,7 
samples were annealed in 30 seconds, while in Lanes 2,4,6,8 samples were 
annealed in 90 minutes. The time did not have much effect on the aggregation of 
the sample. Figure submitted to the journal Acta Crystallographica F. October 
2012 and is currently under review. 
 
As the lower concentration of oligonucleotides at the time of annealing reduced 
the amount of aggregates formed, all samples used for characterization and 
crystallization experiments were annealed at a concentration of 50 nM and further 
purified by size exclusion chromatography. 
 
5.4.4. Other constructs - 20T, 20x30T, and 30T Design, Isolation, and 
Characterization 
In addition to the 20T tetrahedron, two other constructs were designed to 
increase the cavity size. The 20x30T tetrahedron and a 30T tetrahedron (see Fig 
5.7a-b) were annealed and purified. Figure 5.7 shows the purification of the  
20x30T and 30T by size exclusion chromatography and verification of the 
purification procedure by native gel-electrophoresis (see Fig 5.7 c and d).  
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Figure 5.7. Chromatograms of 20x30T (a) and 30T (b) during the purification, 
and the resulting native gel mobility assays of the 20x30T (c) and 30T (d) in 
relation to the 20T, with noticeable mass differences. The samples described here 
were purified using SEC, but in (a) a different column was used with a lower 
volume compared to the column used in (b). Figure submitted to the journal Acta 
Crystallographica F. October 2012 and is currently under review. 
  
5.4.5. Dynamic Light Scattering (DLS) Characterization of 20T Tetrahedron 
X-ray structure determination requires crystals, and monodisperse samples 
are highly desired prior to crystallization. Traces of oligomers formed during the 
annealing step at low DNA concentrations are qualitatively  removed by size 
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exclusion chromatography, but concentrating of the DNA tetrahedrons prior to 
crystallization could lead to reformation of aggregates.  Dynamic Light Scattering 
(DLS) was used as a method to quantify the amount of aggregation present in the 
purified, concentrated DNA tetrahedron sample prior to crystallization. The DLS 
experiments revealed a hydrodynamic radius of approximately 4 nm (diameter 8 
nm) for the monomeric 20T Tetrahedron, which confirms the expected size of our 
construct and these results are also consistent with the dimensions determined by 
cryo-EM. [31] The DLS results show a bi-modal size distribution of the DNA 
before size exclusion purification, with a monomer peak featuring a 
hydrodynamic radius of approx 35 ± 5 nm and an aggregate peak at radius of 
approximately 370nm. DLS data are shown in most publications in form of 
"radius-corrected" scattering intensities (scattering intensity is increased with r6), 
which leads to suppression of aggregate peaks. However, we aimed for the 
detection of even small traces of aggregates and therefore we present the raw DLS 
data without "radius corrections" in Figure 5.8. Figure 5.8a shows the unpurified 
20T tetrahedron at a concentration of 2.5 mg ml -1 in 1X TAE-Mg2+ buffer before 
SEC purification. Two main peaks indicating a hydrodynamic radius of 3.4 nm 
and 37 nm  with a large shoulder towards higher molecular weight aggregates 
appear. 5.8b shows the purified sample at a concentration of 2.5 mg ml -1, 
indicating a monomer peak of ~4 nm and smaller aggregate peak at a size of 143 
nm. 
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Figure 5.8. Dynamic Light Scattering measurements comparing unpurified and 
purified 20T tetrahedron. Figure submitted to the journal Acta Crystallographica 
F. October 2012 and is currently under review. 
 
Figures 5.8c and 5.8d show the distribution plot of unpurified 20T (5.8c) showing 
more aggregates than the purified sample in 5.8d. The quantification of 
aggregates is summarized in Table 1. The evaluation of the data is based on peak 
integration, size of the aggregates and number of tetrahedrons per aggregate. The 
evaluation shows that the ratio of proteins that are present in from of aggregates 
versus monomers decreased from 3 10-4 before purification to 3.2 10-6 after 
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purification and ultrafiltration of the samples prior to crystallization. DLS can also 
be used to further study the crystallization process of  
 before SEC 
purification 
purified,  concentr. 
sample 
∫ aggregate peak (au) 0.5 0.28 
∫  of monomer peak (au) 0.09 0.22 
radius of aggregate peak 
(nm) 
38 143 
radius monomer peak(nm) 3.5± 0.5 4.6± 0.5 
∫  / r6  aggregate 1.8 10-10 3.17 10-14 
∫  / r6 monomer 5.4 10-5 2.26 10-5 
∫  / r6  aggregate/∫  / r6 
monomer 
3.3 10-6 1.4 10-9 
MW of aggregate  8 106 1.84 108 
MW of monomer (Da) 8 104 80 104 
no of monomers per  
aggregate 
100 2300 
∫  / r6  aggregate/∫  / r6 
monomer 
x no of monomers per 
aggregate 
= ratio of number of DNA 
molecules present in 
aggregates/ no of DNA 
molecules in monomers  
3.3 10-4 3.22 10-6 
 
Table 1. Data evaluation of Dynamic Light scattering results. 
 
 
the tetrahedron – from initial set up of the hanging drop, to nucleation, and the 
growth of the crystals [45].  
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5.5 TETRAHEDRON CRYSTALLIZATION 
5.5.1. Crystallization results 
In the first step in the crystallization process, we screened a large amount of 
conditions using sparse matrix screens (Sigma, St. Louis, MO). Initial screening 
indicated crystallites in the following conditions:  
• 50 mM cacodylate pH 6.0, 20 mM argininamide, 1 mM barium chloride, 2 
mM spermidine hydrochloride, 30% PEG 400 
• 50 mM HEPES pH 7.0, 1 mM cobalthexamine chloride, 35% PEG 400 
• 50 mM cacodylate pH 6.5, 20 mM lithium chloride, 5 mM cobalt (II) 
chloride, 35% PEG 600 
• 50 mM HEPES pH 7.0, 20 mM ammonium chloride, 5 mM MgCl2, 35% 
PEG 600 
• 1 mM cobalthexamine chloride, 2 mM putrescin hydrochloride, 35% PEG 
600 
• 50 mM cacodylate pH 6.0, 20 mM argininamide, 1 mM cadmium 
chloride, 30% PEG 1000 
 
Comparing the conditions, we noticed that all crystallization conditions that 
produced initial hits had a pH between 6.0-7.0. Most of the crystals were very 
small and showed visible defects, such as being hollow or clustered. Crystals 
grown using PEG-1000 as the precipitant analyzed for their diffraction at 
synchrotron sources and a resolution of ~10Å was observed. We screened 
multiple additives including argininamide, which gave the initial hit to improve 
crystal quality. Most of these additives contained the positively charged amine 
groups that may aid in stabilizing the structure of the DNA via electrostatic 
interactions by minimizing charge repulsion of the phosphate backbone [60,61]. 
After several round of optimization, optimized conditions were established in 29-
34% PEG-1000, 10-25 mM L-argininamide, and 50 mM sodium cacodylate pH 
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6.0 using the hanging-drop vapor diffusion technique. Crystal sizes in the sitting 
drop setup ranged from approximately 50-100 µm in conditions with higher PEG 
1000 concentrations to 100-500 µm at the largest with lower PEG 1000 
concentrations ranging from 28-32%. Under optimized conditions, tetrahedron 
crystals grew in approximately 2-3 days at 23°C. The crystal shape was 
consistently rectangular, colorless, and transparent, but even after optimization, 
many crystals showed visible defects. Figure 5.9a shows a large crystal grown in 
50 mM sodium cacodylate pH 6.0, 10 mM L-argininamide, and 29% PEG-1000. 
The large crystal was 400 µm long and 40 µm thick. Figure 5.9b shows crystals 
grown in an experiment under similar conditions with the use of human hair as a 
seed. These crystals were grown in 50 mM sodium cacodylate pH 6.0, 15 mM 
argininamide, and 32% PEG-1000. Most of the crystals grew on the surface of the 
hair and their average size was 50 µm in length and 10 µm in diameter. They also 
displayed a more solid and stable appearance during crystal handling, mounting 
and freezing. These smaller crystals showed less defects than the larger ones.  
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Figure 5.9. Crystal size comparison of largest crystals observed. DNA 
tetrahedron crystals grown in varying conditions. In 5.9a, crystals were grown in 
50 mM sodium cacodylate pH 6.0, 10 mM L-argininamide, and 29% PEG-1000. 
In 5.9b, crystals were grown in 50 mM sodium cacodylate pH 6.0, 15 mM 
argininamide, and 32% PEG-1000 in the presence of human hair. Figure 
submitted to the journal Acta Crystallographica F. October 2012 and is currently 
under review. 
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We tested a large range of cryo-protectants and best freezing conditions were 
established by use of a cryo-solution that contained 1.2-2 times higher 
concentration of precipitant, buffer, and salt than the reservoir solution. Upon 
incubation in cryoprotectant solutions for 30 minutes, the crystals were mounted 
in 0.05-0.2 mm loops and were flash-frozen in liquid nitrogen. Crystallization of 
the 20x30T and 30T was also attempted. However, crystallization trials so far did 
not yield crystals. We speculate that the increase of  the tetrahedron size may 
allow for higher structural  flexibility, which might be problematic for crystal 
formation.  
 
5.5.2. Optimization of results to grow higher quality crystals 
Seeding 
Seeding experiments were attempted with the goal of growing higher 
quality crystals through heterogeneous nucleation using human hair. The crystals 
produced using heterogeneous nucleation are shown in Figure 5.9b, and there is 
an observable solidity in these crystals compared to crystals produced in 
traditional vapor diffusion methods without seeding. The crystals were 
significantly smaller, and some grew directly on the surface of the hair. In 
examining the crystals closely, there was no obvious splits or jagged edges like 
what was frequently seen in other crystals. See further text in this chapter for an 
analysis of x-ray diffraction quality of these crystals. 
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5.5.3. Role of magnesium and different magnesium salts 
The use of divalent cations in DNA preparations is very prevalent due to 
their interaction with the phosphate backbone. During the annealing step in 
preparing the tetrahedron, 12.5 mM magnesium acetate was present in the buffer, 
1X TAE-Mg2+. The tetrahedron was purified using different concentrations of the 
buffer, such as 2X and 5X TAE-Mg2+. However, if the concentration of 
magnesium acetate was too high, more aggregates were present on the 
chromatogram during the purification. Therefore, different magnesium salts were 
tested such as magnesium chloride and magnesium sulfate in the crystallization 
screen solutions. In an attempt to further improve crystal quality, magnesium was 
used as an additive in the crystallization screens. However, this did not 
significantly change the crystal quality.    
 
5.5.4. Importance of additives including argininamide 
It is well understood that argininamide plays an important role in 
stabilizing the negatively-charged phosphate backbone of the DNA [61]. Through 
electrostatic interactions, the argininamide offers a bridge between dsDNA edges 
that would otherwise repel each other. Argininamide is also present in many 
DNA-protein aptamer crystal structures [60]. In the case of the crystallization 
trials of the 20T tetrahedron, the crystal screen solutions containing the 
argininamide produced the highest quality crystals in the entire suite. Other 
additives that were further explored include cobalt hexammine, spermidine, and 
spermine. All of these offer positively charged amine groups that aid in stabilizing 
  102 
the negatively charged DNA backbone, and could aid in the formation of more 
crystal contacts, but the best results so far were obtained with argininamide.  
 
5.5.5. Exploring pH and changing the buffer conditions in crystallization screens 
As shown in the tables in the Materials and Methods and Appendices, 
crystallization screens were developed that contained different buffer systems that 
would alter the pH of the overall screen solution. The best conditions for the 20T 
crystals were 29-34% PEG-1000, 15 mM L-argininamide, and 50 mM sodium 
cacodylate pH 6.0. Screens were developed using Tris, Tris-sodium cacodylate, 
and MES.  The results showed that crystals grew even in the conditions where the 
pH was 9.0. The best crystals grew in a pH of 9.0 and 7.0. The crystals appeared 
smaller and indicate less visual defects than crystals grown in a pH of 6.0. See 
Figures 5.10-5.11 for images of the crystals grown using the different pH 
conditions.  
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Figure 5.10. 20T tetrahedron crystals grown in 50mM MES pH 6.0, 15mM 
argininamide, and 30% PEG-1000.  
 
 
 
 
 
 
 
 
 
 
Figure 5.11. 20T tetrahedroncrystals grown in 50mM Tris pH 9.0, 15mM 
argininamide, and 30% PEG-1000.  
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5.5.6. Crystal dehydration experiments 
In another attempt to improve the diffraction quality of the 20T 
tetrahedron crystals, the crystals were dehydrated prior to freezing and mounting 
for x-ray data collection. As shown in Figure 5.12 below, the setup involved 
transferring the crystals into 10 µL of a solution containing 35% PEG-1000, 
10mM argininamide, and 50mM sodium cacodylate pH 6.0 on the post of a sitting 
drop tray. In the reservoir, 1000 µL of a screen solution containing 50% PEG-
1000, 10mM argininamide, and 50mM sodium cacodylate pH 6.0 was added. The 
very high concentration of the precipitant "dehydrated" the crystal via vapor 
diffusion so as to produce a more densely-packed crystal. As shown in Figure 
5.13 below, no degradation of the crystal occurred, even after incubating the 
crystals overnight.  
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Figure 5.12. Schematic of 20T tetrahedron crystal dehydration.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13. Images of the 20T tetrahedron crystals taken before and after 
dehydration. Crystals were incubated in the higher PEG-1000 solution overnight 
and still remained intact.  
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5.6. X-RAY DIFFRACTION DATA ANALYSIS 
5.6.1. Conventional x-ray crystallographic data analysis of 20T tetrahedron 
crystals 
X-ray diffraction experiments were conducted at the Advanced Light 
Source at Lawrence Berkeley National Laboratory at Beamline 8.2.1 and the 
Advanced Photon Source at Argonne National Laboratory at Beamline ID-19. 
The  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. Single x-ray diffraction pattern of 20T crystals to a resolution limit 
of approximately 3.4Å. Figure submitted to the journal Acta Crystallographica F. 
October 2012 and is currently under review. 
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wavelength of the x-ray beam was 1 Å, photon flux was 1012 photons sec -1, and 
the oscillation range was in most cases 1° per image, and the average exposure 
time was 3 seconds. The crystals were aligned in a cryo-stream of liquid nitrogen 
at a distance of 500 mm from the detector, and the detector size at APS was 3072 
x 3072 pixels. Initial x-ray data analysis indicated poor diffraction to 10-20 Å. 
The use of argininamide lead to the improvement in the resolution to 6-7 Å. 
Further optimization lead to even greater improvement to a resolution limit of 3.4 
Å. One of the 3.4 Å diffraction patterns is shown in Figure 5.14. We collected a 
data set of ~200 images on the crystals which show that they are highly 
anisotropic. Furthermore, the small crystals are very prone to x-ray damage so 
only 1-3 images could be collected. Subsequent images showed a degradation of 
the crystals, as shown in Figure 5.15. Figure 5.15a shows the very first image 
captured and 5.15f shows the crystal towards the end of the data collection. In the 
beginning of the data collection, spots are visible which represent a pattern 
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Figure 5.15. X-ray diffraction on a single 20T tetrahedron crystal over time. 
Figure submitted to the journal Acta Crystallographica F. October 2012 and is 
currently under review. 
 
 
more characteristic of diffraction-quality crystals; whereas in 5.15f the spots not 
only diminish, but become very broad and faint. We also attempted data 
collection on the small crystals (~50 µm in size). However these small crystals 
were even more sensitive to x-ray exposure, and only about 3-20 images could be 
collected before the peaks diminished, with the smallest crystals decaying faster 
than larger ones.  
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5.6.2. Crystallographic Data Analysis  
Although limited data were collected due to radiation damage and 
anisotropy of the crystals, a first approximation of the unit cell constants could be 
determined. The 20T tetrahedron crystallizes in unit cell C2 with unit cell 
dimensions of a=105, b=171, c= 59.4 Å, α = 90, β = 92.7, and γ = 90. The unit 
cell dimensions are  consistent with 2 tetrahedron molecules per asymmetric unit 
assuming a solvent content of 50%.  
 
 
5.6.3. X-Ray Damage Investigations 
In order to test if the tetrahedron was stable following exposure to 
synchrotron radiation, 20T crystals which had been used for data collection were 
dissolved in loading buffer containing bromophenol blue and xylene cyanol FF 
and applied onto a 5% native gel. Lanes 2-4 in Figure 5.16 contain 20T crystals 
from conditions in a screen ranging from 28-38% PEG-1000, 10-25 mM L-
argininamide, and 50 mM sodium cacodylate pH 6.0. The results of the native gel 
electrophoresis (see Fig. 5.16) shows that the DNA tetrahedron monomer remains 
intact during exposure to synchrotron radiation, but this does not exclude damage 
to individual bases or destruction of crystal contacts. The radiation damage 
problem is the most detrimental obstacle for the x-ray structure determination of 
the tetrahedron. Radiation damage poses serious complications for nucleotide 
crystallography. Upon reaction with singlet oxygen or hydroxyl radicals, guanine 
is converted into 7,8-dihydro-8-oxoguanine (GO). The GO can still form a base-
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pair with cytosine, but also incorrectly pairs with adenine. [62] This phenomenon 
would distort the structure of the tetrahedron. In vivo, DNA is also one of the 
most radiation sensitive biomolecules in the cell and sophisticated damage 
checkpoints and repair mechanisms exist, including  the base excision repair 
mechanism, started by DNA glycosylases which recognize the damaged bases and 
excise them. [63,64] Additionally, the large tetrahedron crystals were not well-
ordered in all dimensions,  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16. 5% native-PAGE of dissolved 20T crystals after exposure to 
synchrotron radiation. The first two lanes of the gel indicate only one or two 
crystals that were dissolved in tracking dye directly from the cryoloop, and the 
third lane indicates purified tetrahedron as a control. The bands match, indicating 
that no degradation of the DNA tetrahedron occurred.  
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resulting in anisotropy. The  anisotropy of the crystal and the decay due to x-ray 
damage over time and space in the presence of the x-ray exposure shown in 
Figure 5.15 may be caused by a combination of radiation damage effects and 
effects of crystal anisotropy. It would be interesting to study in the future if the 
crystals could be improved by incorporation of a protein or peptide sequence 
inside of the tetrahedron to stabilize the tetrahedron within the crystal and reduce 
the anisotropy.  
 
5.6.4. Microfocus beamline results 
In order to examine multiple points along the same crystal to test for 
crystal defects, and to collect data on microcrystals, microfocused beams 
possessing diameters ≤10 µm were used. This also allowed for “scanning” of the 
crystal for both strong and weak diffracting points. As expected, certain regions of 
the crystals showed a higher degree of disorder compared to others. The 
microfocusing capability of the Advanced Photon Source Beamline ID-19 
provided a straightforward strategy toward examining the apparent anisotropy of 
the tetrahedron crystals.  
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Figure 5.17. Microcrystals of 20T tetrahedron grown in higher PEG-1000 
concentrations, and the loops used in x-ray diffraction experiments. The 
microcrystals were approximately 50 µm long and 10 µm wide.  
 
5.7 TOWARDS NANOCRYSTALLOGRAPHY 
In X-ray crystallography, freezing and X-ray structure analysis of the 
crystals under cryogenic conditions (77-100K) reduces the secondary radiation 
damage of the sample [65] , but even under cryogenic conditions 85% of the X-
rays are absorbed leading to X-ray damage while  only 5% are scattered [66].  
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Figure 5.18. 20T tetrahedron crystals grown in varying PEG concentrations with 
the goal to grow micro/nanocrystals. Figure submitted to the journal Acta 
Crystallographica F. October 2012 and is currently under review. 
 
 
Therefore a method is highly desired which would bypass the x-ray damage 
process altogether like data collection on hundreds of microcrystals using 
microfocused beamlines, and eventually analyzing nanocrystals by femtosecond 
nanocrystallography. Figure 5.18a-c shows the development towards the 
production of small crystals of the tetrahedron. Figure 5.18a shows crystals grown 
in 50 mM sodium cacodylate pH 6.0, 10 mM L-argininamide, and 30% PEG-
1000, 5.17b shows crystals grown in 50 mM sodium cacodylate pH 6.0, 10 mM 
L-arginininamide, and 31% PEG-1000, and 5.17c shows crystals grown in 50 mM 
sodium cacodylate pH 6.0, 10 mM L-argininamide, and 32% PEG-1000. The 
crystal size visibly decreased with the higher PEG concentration. In 5.18a, the 
crystals were approximately 200-300 µm long, 100 µm long in 5.18b, and 
approximately 50 µm long in 5.18c. The ideal method to solve the x-ray structure 
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of the tetrahedron would avoid radiation damage using the diffract before destroy 
principle established in the new method of ther, such as testing microcrystals at a 
microfocused beamline, or using femtosecond nanocrystallography, [67,68] where 
millions of diffraction snapshots are collected from a stream of nanocrystals at 
room temperature by the use of femtosecond free-electron lasers.  
 
5.7.1. Femtosecond Nanocrystallography Results 
20T tetrahedron crystals were produced for analysis using the free-
electron laser at the Linac Coherent Light Source beamline at Stanford. In order to 
successfully pass through the lines of the injector, the crystals could not be larger 
than 20 µm at their largest dimension. Crystals of the tetrahedron were produced 
during initial LCLS attempts; however, the size was no smaller than 30 µm and 
the crystals did not pass through the filter. During the next set of LCLS 
experiments, purified tetrahedron was crystallized on-site but due to material 
quantity limitations, the volume of the nanocrystal suspension was too small (100 
µL) to be used for data collection. Future plans at the LCLS include an 
experimental scale-up of the tetrahedron preparation to provide enough crystals 
for one full data set to be collected. Beamtime (5 12-hour shifts) have been 
awarded at LCLS for the DNA crystals which will be scheduled in Spring 2013.  
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5.8 PEPTIDE CONJUGATION TO DNA 
 5.8.1. SYNTHESIS OF PEPTIDE SEQUENCES FOR THE 
DEVELOPMENT OF AN ARTIFICIAL OXYGEN EVOLVING COMPLEX 
 
Conjugation strategy and designing a chemical linker 
In order to design the aOEC, the peptides needed specific conjugation sites 
within the tetrahedron. A close-up view of the peptide sequences that are used in 
this work is shown in Figure 5.19. In natural PSII, these sequences provide the 
necessary amino acids that are MnCa cluster ligands. Therefore, synthetic 
sequences are used in this work also with the goal of ligating the MnCa cluster. In 
order to facilitate the encapsulation of the peptide sequences, a three-dimensional 
DNA tetrahedron is necessary as the stable framework. A schematic picture of 
this framework and the encapsulated synthetic aOEC is based on the natural 
protein environment in PSII and is shown in Figures 2.2-2.3. Based on that 
design, five proposed conjugation points as needed inside of the tetrahedron – two 
for the yellow sequence shown in Figure 5.20 (156-195-D1), two for the red 
peptide (347-360-CP43), and only one for the green peptide (CT-D1). Therefore, 
multiple covalent linker chemistries were devised. The first one 
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Figure 5.19. A closer view of the peptide environment surrounding the Mn 
cluster, emphasizing the CT-D1 peptide (shown in green). Adapted from pdb file 
2AXT.  
 
 
successfully conjugated was the CT-D1 peptide, the C-terminal peptide providing 
four ligands to the Mn cluster. The peptide was synthesized with a maleimide 
functional group at the N-terminus for coupling to a thiol-modified DNA base. 
The thiol sulfur reacted with the maleimide group to form a covalent bond in the 
presence of reducing agent, TCEP, to prevent undesirable side reactions. See 
Figure 4.6 for the reaction scheme.  
 
 
 
 
 
Figure 5.20. Schematic of artificial Oxygen-Evolving Complex organized in a 3D 
DNA tetrahedron. Figure courtesy of Chenxiang Lin. 
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Synthesis results and analysis of sequence 
 The “green” peptide sequence, named CT-D1 for C-terminal D1 subunit, 
was synthesized as described in Materials and Methods and purified using a C4 
reverse-phase column. Tryptophan residues were added near the N-terminal end 
to allow for  detection of fluorescence. The peptide sequence is shown in Figure 
5.21. Additionally, glycine residues were also added to allow for flexibility near 
the conjugation site. Providing a connection site that was too rigid would possibly 
cause conformational changes in the tetrahedron. In order to verify that the large-
scale purification of the peptide via reverse-phase chromatography was 
successful, the peptide was analyzed on a denaturing SDS gel, which showed a 
single-band product. See Figure 5.22.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21. Proposed peptide sequences for aOEC design (top), emphasizing the 
CT-D1 sequence that has been synthesized and characterized so far. The green 
arrows indicate ligands to the MnCa cluster. The peptide synthesis was completed 
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by incorporating maleimidopropionic acid (top portion of bottom image), and 
GWGGWGG as the linker and later this maleimidopropionic acid group was 
chemically modified to obtain maleimide group (bottom portion of bottom 
image).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22. MALDI-TOF of the CT-D1 peptide sequence. The sample was 
mixed with a cinnaminic acid resin before drying. The inset shows the ~4 kDa 
single-band product after analyzing on a 20% Tricine-SDS-PAGE gel.  
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Secondary structure assignment 
The CT-D1 peptide was characterized using circular dichroism (CD). 
Circular dichroism is used extensively to characterize a protein or a peptide’s 
secondary structure. Biophysical characterization in this case is critical because 
the synthetic peptide described in these experiments must be as close as possible 
to its native counterpart for proper functionality. CD wavelength scans from 180-
280 nm showed a minimum at 202 nm and a peak at 225 nm, indicating that the 
peptide was in a random coil conformation. The results show (See Figure 32) that 
the CT-D1 peptide did not fold on its own into the same conformation as the 
native peptide in PSII, as in the PSII complex the C-terminal region of the D1 
subunit is approximately 50% alpha helical and 50% random coil. See Figure 5.23 
for the image depicting the secondary structure of the CT-D1 peptide in its natural 
environment. The synthetic peptide in this case was in the random coil 
conformation and did not display any alpha helical content in 1X TA-Mg2+ 
buffer. (EDTA was eliminated from the sample buffer due to its UV absorbance 
properties). Typically, alpha helical proteins display minima at 208 and 220 nm. 
[69]  
 
Manganese titrations 
In nature, the manganese cluster is directly coordinated by the amino acids 
of the three peptide sequences. However, the cluster is deeply embedded into the 
lumenal side of PSII so that we cannot exclude that a larger second 
“coordination” sphere may be required for stabilization and assembly of the 
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cluster. The conformation of the peptide environment surrounding the manganese 
cluster depends on the presence of all of the amino acids. Manganese (II) sulfate 
was titrated into the CT-D1 sample at increments of 10mM in order to test if the 
conformational change may be induced upon metal binding. Mn(II) was not 
expected to significantly change the conformation of the peptide, considering that 
in nature the manganese cluster is composed of high valent Mn species (Mn(III) 
and Mn(IV)), and the cluster disassembles upon reduction of Mn(III) or Mn(IV) 
to Mn(II). Results shown in Figure 5.25 show that the addition of Mn(II) did not 
affect the secondary structure of the peptide, even at higher concentrations. There 
are two explanations why the peptide does not fold or bind Mn(II). First, the Mn 
may be required to be in the (III) or (IV) oxidation state to bind the peptide. Also, 
it is possible that all three peptides and the Ca2+ are required for the folding and 
assembly. Future experiments will aim at stabilizing the Mn(IV) in aqueous 
solution which would be a pre-requisite to repeating the titration experiments with 
Mn(III) or Mn(IV).   
 
 
 
 
 
 
Figure 5.23. Secondary structure of the CT-D1 peptide sequence indicating 
approximately 50% alpha helical and 50% random coil in its natural environment. 
The C-terminal region is located at the random coil side. (pdb file 2AXT). 
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Figure 5.24. CD wavelength scan of 35aa peptide in 1X TA-Mg2+ buffer (40mM 
Tris base, 20mM acetic acid, 12.5mM magnesium acetate). EDTA was left out of 
this buffer solution due to its interference with the scan. 
 
 
 
 
 
 
 
Figure 5.25. Manganese (II) titrations with the 35aa peptide. No obvious 
secondary structure changes were observed upon the addition of metals. The Mn 
would likely need to be in the Mn(III) or Mn(IV) state in order to induce a 
conformational change. 
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Results of covalently coupling to DNA 
In the first step of building the aOEC, the CT-D1 peptide was coupled to 
the ssDNA strand 4 of the tetrahedron, and the details of the conjugation are 
outlined in the Materials and Methods. The coupling of the ssDNA to the CT-D1 
peptide was done as described in Materials and Methods. A thiolated DNA base 
was reacted with a maleimide-functionalized peptide. The coupling of the CT-D1 
peptide was confirmed through a denaturing PAGE gel mobility assay, as shown 
in Figure 5.26.  This revealed that when the peptide was bound, as expected, the 
conjugate ran at a slightly higher molecular weight. This was due to the fact that 
the peptide added ~3.4 kDa of mass to the DNA. 
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Figure 5.26. 10% denaturing PAGE gel-mobility assay comparing the molecular 
weight change of the thiolated ssDNA strand 4 before the peptide coupling (right 
lane on the gel) and strand 4-peptide conjugate crude product (left lane on gel). A 
mass change of approximately 3.4 kDa resulted after the peptide conjugation The 
line at 2 indicates the conjugate band, while the line at 1 indicates the thiolated 
DNA strand 4 band.  
 
 
Crystallization experiments 
After annealing and purifying the 20T-CT-D1 peptide conjugate, the 
sample was concentrated to 2 mg ml-1 and crystallized using PEG-1000, 
argininamide, and sodium cacodylate pH 6.0. Crystals formed in approximately 
one week and were grown at 18°C. The DNA-peptide conjugate crystallized in 
29% PEG-1000, 10mM L-argininamide, and 50 mM sodium cacodylate pH 6.0. 
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See Figure 5.27 for crystal images. The crystallization results served as a 
confirmation that one of the PSII peptide sequences was successfully synthesized, 
purified, conjugated, assembled, and crystallized. See Figure 5.27 below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.27. Crystals of the tetrahedron-peptide grown in 29% PEG-1000, 50 
mM sodium cacodylate pH 6.0, and 10 mM L-argininamide.  
 
Fluorescence microscopy of DNA-peptide crystals 
We had introduced four Trp residues at the N-terminus of the peptide to 
allow for detection of the CT-D1 peptide by tryptophan fluorescence. Therefore, 
fluorescence microscopy was used to detect the peptide inside of the DNA-
peptide crystals. The Trp fluorescence signal of the crystals was clear, as shown 
in Figure 5.28. The fact that we can detect the crystals by Trp fluorescence likely 
confirms  that the peptide crystals indeed contain the tetrahedron conjugate and 
that the two were crystallized together. Future peptide constructs may also include 
Trp residues for use in fluorescence microscopy on crystals. The fact that the 
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tetrahedron-peptide conjugate crystallized under similar conditions as the empty 
DNA tetrahedron indicated that most likely the peptide is located inside of the 
cage after annealing. This result is very encouraging as it shows that the first 
milestone in the assembly of the PSII aOEC was reached. 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.28. Fluorescence microscopy of tetrahedron-peptide crystals. The image 
is of a crystallization drop of approximately 2 µL.  
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5.8.2. PORPHYRINS AS “TEST” METAL CLUSTERS – ASSEMBLY AND 
CHARACTERIZATION 
One of the key experiments in our work in redesigning the OEC resides in 
the characterization of assembled metal clusters. In this work, porphyrins are used 
as "test" metal cofactors, as they can be modified with several different 
macrocycle constituents, central metals, and axial ligands, and can be rendered 
soluble in aqueous solution. A large variety of porphyrins have been synthesized 
and characterized using UV-Vis spectroscopy and EPR. A central metal can be 
inserted into the porphyrin macrocycle that is paramagnetic and can be thus 
characterizable by EPR. The aforementioned spectroscopic techniques are 
important to the characterization of metal complexes, especially in the final aOEC 
construct which will contain high-valent manganese which is EPR active. As a 
proof of concept, metal-containing porphyrins, specifically Fe(III) meso-Tetra(4-
sulfonatophenyl) porphyrin chloride, have been implemented for testing of the 
encapsulation of a metal-containing molecule inside of the DNA cage. Upon 
coordination of two orthogonally oriented peptides covalently attached to the 
DNA tetrahedron which contain terminal histidine residues, iron (III) switches 
from its EPR-active state (high-spin) to its hexacoordinated low-spin state (a total 
of six nitrogen ligands – two axial and four planar), as depicted in Figure 5.29, 
and the assembly can be analyzed using EPR and UV-Vis spectroscopy.  
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Figure 5.29. The porphyrin used in this work, Fe(III)-meso-Tetra(4-
sulfonatophenyl) porphyrin chloride (Fe(III)-TPPS4), shown in (a). The 
coordination of Fe(III) via two more nitrogens is shown in (b). This is the 
proposed coordination used to assemble the peptides inside of the tetrahedron.  
 
   
 
 
 
 
 
 
  
Figure 5.30. Schematic picture of the self-assembling porphyrin to the terminal 
histidine residues of the two P8 peptides (CAGAGSWH) covalently attached to 
DNA bases on strand 4 of the tetrahedron.  
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Peptide conjugation techniques and results 
Figure 5.30 shows a schematic picture of the self-assembling properties of 
the peptides and porphyrin inside of the 20T tetrahedron. Two thymines with 
amine modifications were introduced into strand 4 of the tetrahedron which 
served as the conjugation sites for the peptides. See Figure 4.8 in Materials and 
Methods for the reaction scheme. The peptide sequence designed for the 
coordination of the porphyrin inside the cage was CAGAGSWH and is referred to 
as P8. This short 8aa sequence is approximately 2.4 nm in length if assuming that 
it does not fold into a  secondary structure. The sequence contains a cysteine so 
the sulfur group could react with the maleimide of the heterobifunctional 
crosslinker SMCC to form a covalent bond between the DNA and the peptide. 
(Figure 4.8 in Materials and Methods). The amine-modified DNA strand was 
reacted for 3 hours at room temperature with a 100-fold excess of SMCC in 
acetonitrile. The reactive NHS ester group of the SMCC reacted with the primary 
amine on the amine-modified thymines of the DNA strand. The excess SMCC 
was successfully removed via two ethanol precipitation steps.. The ssDNA was 
coupled to the peptide via the maleimide group of the SMCC which reacted with 
the cysteine sulfur, as described in Materials and Methods. Thus, the 
heterobifunctional crosslinker served to conjugate ssDNA to the peptides in a 
highly reproducible manner.  
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Using SMCC as a heterobifunctional crosslinker 
The use of SMCC as a crosslinker between nucleotides and peptides is well-
established in the literature [58,70]. The reactive NHS ester interacts with the free 
amine group of the chemically modified DNA base (in this work, Thymine). See 
Figure 4.8 for the reaction scheme. Upon reaction in buffer free of primary 
amines (i.e., no Tris), the excess SMCC is readily separated from the DNA 
through ethanol precipitation steps. After removing excess SMCC, it was possible 
to conjugate a peptide containing a cysteine sulfur via the maleimide moeity of 
the SMCC. 100-fold excess peptide was added to the reaction mixture, which 
ensured that all DNA was conjugated. Following reaction at room temperature 
also in the presence of buffer free of primary amines, excess peptide was removed 
via size-exclusion gravity flow NAP-5 columns, and conjugates are easily 
quantified by measuring A260 for the DNA strand. In the NAP-5 columns, small 
molecules (peptides for example) are left on the column, effectively removing the 
excess peptide from the sample.  
 
MALDI-TOF and gel mobility assay to confirm conjugation 
Before we tried to assemble the ssDNA-peptide conjugates into a 
tetrahedron, the DNA-peptide conjugates were analyzed by electrophoresis. A 
10% denaturing-PAGE gel shift asssay (See Figure 5.31) shows the small size 
difference between uncoupled purified ssDNA and peptide-coupled ssDNA. The 
size difference was approximately 1.5 kDa and was also verified by MALDI-
TOF, shown in Figure 5.32. The expected molecular weight was 21,933 Da and 
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the observed mass was 21,467 Da. MALDI-TOF is notoriously difficult on long 
DNA sequences [59] (we have conjugated a 63-mer), and for this work a low 
concentration of 8 µM DNA-peptide was used.  Therefore, the MALDI-TOF 
spectrum is noisy due to the low concentration and also possibly from residual 
salt remaining from the DNA sample preparation.  In order to overcome the salt 
problem with the long DNA sequences [59], the DNA-peptide conjugate was first 
mixed with a DOWEX resin to remove excess salt, and then it was mixed with an 
excess of a saturated solution of 3-hydroxypiccolinic acid as the matrix.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.31. Results of denaturing-PAGE gel shift, indicating a slight mass 
change in the DNA-peptide conjugate.  
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Figure 5.32. MALDI-TOF confirming conjugation of two peptides to the ssDNA, 
adding ~1.5 kDa of mass to the DNA strand.  
 
Strategies for assembling tetrahedron-peptide-porphyrin complex (20TP8P) 
Two strategies were employed for assembling the complete DNA cage 
with the peptides and porphyrin assembled inside, as indicated in Figure 4.7. One 
strategy, Scheme 1 (See Figure 4.7), required assembling the strand 4-peptide 
conjugate to the other three strands followed by the purification of this complex 
using SEC. The porphyrin was then introduced into solution, assuming it would 
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migrate into the center of the tetrahedron given that our calculations indicated that 
there would be enough space on each face of the tetrahedron for the porphyrin to 
enter into the cage. An alternative method, Scheme 2, involved mixing the strand 
4-peptide conjugate with the porphyrin first, and then annealing the other 3 
strands together but at a higher concentration of at least 5 µM  porphyrin and 5 
µM of the tetrahedron strands due to the fairly high dissociation constant of 2 µM 
that was calculated for the peptide-porphyrin binding. Calculations for the 
peptide-porphyrin Kd were performed by titrating the porphyrin with peptide.  
 
 
Assembly of the 20TP8P Complex - Scheme 1 
Following conjugation of the peptide to the ssDNA, annealing of the entire 
construct was performed by mixing the strands in equimolar concentration (50 
nM) in 1X TAE-Mg2+ pH 8.0, heating to 90°C, and allowing the sample tubes to 
cool to room temperature over the course of 90 minutes. After concentrating the 
sample from approximately 450 mL to 500 µL, it was loaded onto a Superdex 200 
size-exclusion column. As shown in Figure 5.33, the chromatogram indicates that 
the monomeric construct elutes around 65 minutes, which is similar to the elution 
time of the empty 20T tetrahedron, which elutes between 60-65 minutes. This 
result would be consistent with the assumption that the peptides are located in the 
center of the 20T tetrahedron. If the peptides were oriented outside of the cage, 
the elution time of the 20T peptide conjugate would decrease because the 
hydrodynamic radius of the structure would increase. The chromatogram shows 
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that few aggregates were formed during the annealing step. Following HPLC SEC 
purification, the monomeric tetrahedron-peptide complex was concentrated to 10 
µM for porphyrin assembly. 
 
Figure 5.33 Size-exclusion chromatogram of 20T-peptide conjugate purification 
before the addition of porphyrin. A260 is shown in blue, and A280 is shown in 
red.  
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UV-Vis Spectroscopy of Peptide-Bound and Unbound Porphyrin and Binding 
Affinity of Bis-Histidine Coordinated Porphyrin 
Tests were conducted to ensure that the terminal histidine residue of the 
peptide bound to the porphyrin’s Fe(III) center. Bis-histidine coordination of 
Fe(III)-containing porphyrins is investigated in the literature [71,72,73]. A ~8 nm 
hyperchromic red shift in the Soret region occurs upon bis-histidine coordination 
of the porphyrin. A similar Soret shift in was observed when our P8 peptide was 
mixed with our Fe(III)-TPPS4 porphyrin in solution. Additionally, our spectra 
showed two Q bands in the 500-600 nm region in its unbound form. Upon binding 
to His residues of the peptides, only one slightly blue-shifted Q band is observed. 
Titrations revealed that a maximum binding occurred when 3 equivalents of 
peptide were added to the porphyrin. Calculations for the dissociation constant for 
the complexation of the bis-His-Fe(III) resulted in Kd1 =  2 µM, and Kd2 = 40 
µM. The first dissociation constant refers to the first complexation event in which 
one histidine is bound to the Fe(III). These Kd values were obtained by plotting 
A416 (approximate Soret maximum for all bis-His-Fe(III) species) against the 
concentration of the ligand (peptide), and using a log plot to obtain the values, as 
described in [74]. More detailed calculations are currently in preparation.  
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Figure 5.34. Hyperchromic red shifts associated with increasing concentrations of 
peptide (ligand) for the porphyrin. Unbound Fe(III) porphyrin exhibits a Soret 
peak at 408 nm while bis-histidine coordinated Fe(III) exhibits a 416 nm peak. 
The legend indicates the molar ratio at which ligand (peptide) was added. 1eq 
means 1 molar equivalent of peptide compared to the porphyrin (in these spectra, 
5 µM was always the concentration of porphyrin).  
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Figure 5.35. Titration of porphyrin with different equivalents of peptide—an 
observable decrease in absorption is accompanied by a shift, indicative of 
pentacoordinated species, until approximately 6 equivalents of peptide, at which 
the shift again becomes hyperchromic, likely indicating the formation of 
hexacoordinated species. These absorbance values at 416 nm were used for the 
plot to calculate the dissociation constant for this reaction.  
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EPR to investigate spin state of iron 
EPR has been used extensively to study metalloproteins, or proteins 
containing cofactors with central metals. Hemes or porphyrins are cofactors in 
many biological systems. Most of the work done on iron-containing porphyrins 
revolves around heme cofactors in both hemoglobin/myoglobin and cytochromes 
[75]. EPR is a very powerful technique when working with coordination of 
transition metals. In this work, iron is the transition metal studied. The high-spin 
ferric iron is EPR active, possessing unpaired electrons, and low-spin iron can be 
observed upon bis-histidine coordination [76]. The nature of the iron coordination 
and the spin state of ferric heme complexes was examined earlier in de novo-
designed heme proteins. [73] The transition of the free porphyrin to the porphyrin 
with bis-histidine coordinated iron(III) can be detected by EPR. Both high-spin 
and low-spin iron(III) possess specific g values as described in [75]. High-spin 
iron(III) has a value of g = 6.2, whereas low-spin bis-histidine-coordinated 
iron(III) has g values of approximately 3.03, 2.23, and 1.43. The reason for this is 
that the axially coordinated ligands cause the iron(III) to become low-spin.  
 
EPR of peptide-bound porphyrin and unbound porphyrin 
Given that the spin state of the Fe(III) species changes upon this 
coordination, we measured EPR spectra of the unbound porphyrin and collected 
EPR spectra of the bound porphyrin with different concentrations of peptide. 
Many tests were conducted with different concentrations of ligand, which in these 
experiments, is the peptide. In Figure 5.36, CW EPR spectra of free porphyrin and 
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3 titrations of porphyrin and peptide are shown. The black line represents 
unbound porphyrin at a concentration of 1 mM, red line is 1 mM porphyrin : 1 
mM peptide, green line is 0.5 mM porphyrin : 1 mM peptide, blue line is 1 mM 
porphyrin : 0.5 mM peptide. The ideal range for binding was found to be a 
stoichoimetric ratio of 1 porphyrin : 2 peptides, as expected for this coordination 
of the Fe(III) of the porphyrin. The results revealed the optimal peptide:porphyrin 
stoichiometric ratio that induced the low-spin species to form. High-spin Fe(III) is 
easily detectable in the EPR measurements by the characteristic line at g = 6.2, 
while low-spin Fe(III) formation is detected by its lines at g = 2.93, 2.2, and 1.57. 
The addition of the peptide immediately resulted in a presence of low-spin 
species, indicating that the Fe(III) adopted its octahedral conformation upon 
binding of the two histidine nitrogens. The best yield for the low-spin Fe(III) 
resulted at a 1:2 stoichoimetric ratio of porphyrin to peptide. (See Figure 5.36) 
The transition to the low-spin Fe(III) clearly indicates that two histidines are 
coordinate to the iron. We hypothesize that the black line represents 100% 
unbound porphyrin, the blue line is 75% unbound and 25% bound, the red line is 
50% unbound and 50% bound, and the green line is 100% bound. The green line 
showing the 1:2 stoichiometric ratio of porphyrin to peptide is proof that this 
species is entirely hexacoordinated (two axial histidines are coordinated to the 
Fe(III) of the porphyrin).  
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Figure 5.36. Porphyrin-peptide titrations and associated EPR spectra. A 
noticeable change from high-spin to low-spin occurs upon a 1:2 stoichiometric 
ratio of porphyrin:peptide.  
 
 
The influence of EDTA in Fe(III) porphyrin EPR and UV-Vis measurements 
                    We speculated that in the EPR measurements shown in Figure 5.36, 
an iron chloride contaminant in the sample was causing a line to appear in all of 
the spectra at g = 4.5 that was undesirable. It is likely that the EDTA chelated 
trace amounts of free iron contaminants, causing the line to appear. Therefore, in 
another experiment, the influence of EDTA in the buffer system on the EPR 
spectra was investigated. In Figure 5.37, CW EPR spectra of unbound porphyrin 
and 4 titrations of porphyrin and peptide, with EDTA in the buffer, are shown. 
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The black line represents unbound porphyrin at a concentration of 0.5 mM, red 
line is 0.5 mM porphyrin : 0.5 mM peptide, green line is 0.5 mM porphyrin : 1 
mM peptide, blue line is 0.5 mM porphyrin : 2.5 mM peptide, and light blue line 
is 0.5 mM porphyrin : 5 mM peptide. The ideal range for binding was found to be 
a stoichoimetric ratio of 1 porphyrin : 2 peptides. In the EPR spectra of the 
peptide-porphyrin where EDTA was present, a strong line at g = 4.5 indicated a 
FeCl2 contaminant. Once EDTA was eliminated from the sample, that 
contaminant disappeared. Thus, EDTA was not necessary to include in the sample 
as there was no need to chelate the excess magnesium acetate (source of divalent 
cations for when DNA is in the sample) in the buffer when working with the 
peptide and porphyrin only. UV-Vis measurements revealed no difference in the 
spectra when EDTA was present or absent in the buffer. The typical 
hyperchromic red shift is observed when the peptide is added to the sample. 
Additionally, two Q bands are present in the free porphyrin sample, and when the 
peptide is added, only one Q band is observed. No apparent difference in the UV-
Vis spectra existed between the samples in buffer with EDTA and without EDTA, 
as shown in Figure 5.38.  
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Figure 5.37. EPR of porphyrin and peptide with (left) and without EDTA (right). 
The iron contaminant at g = 4.5 is decreased when EDTA is not in the buffer 
(right).  
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Figure 5.38. UV-Vis measurements of the porphyrin and peptide without EDTA 
in the buffer. These results look nearly identical to the results presented in Figure 
5.33 earlier where EDTA was in the buffer. The presence or absence of EDTA 
does not affect the UV-Vis measurements.  
 
 
Assembly of the 20TP8P complex using Scheme 1 
 The initial assembly strategy for the incorporation of the porphyrin 
involved using Scheme 1, in which the 20TP complex was assembled and purified 
first, and then porphyrin was added. This strategy seemed most promising as it 
effectively removed all of the higher molecular weight aggregates and other 
contaminants in the SEC step before the porphyrin was added. 
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Verification of Internal Assembly of the Porphyrin – DLS and native gel 
electrophoresis 
We explored many different ways of validation that the porphyrin was 
internally assembled inside of the DNA cage, and to exclude the possibility that 
the Fe would be coordinated by inter-20T coordinating that would cause the 
formation of dimers. Native gel electrophoresis (gel mobility assay) and DLS are 
reliable methods to confirm assembly and detect dimers. If multimers of 
tetrahedra formed, they would appear on a gel. Figure 5.40 shows that binding of 
the porphyrin does not lead to the formation of dimers or higher molecular weight 
aggregates. The native gel in Figure 5.40 shows that the 20T-peptide construct 
was successfully purified through size-exclusion chromatography, and that only 
few aggregates are present in the sample. Upon addition of the porphyrin to the 
sample, no aggregation occurs, indicating that intercoordination of the two 
histidines with the Fe(III) is likely occurring inside the cage, rather than 
intercoordination to other tetrahedra. Additionally, in such a dilute sample, 
intercoordination would be unlikely. Since no size change of the 20T-peptide 
construct occurs when the porphyrin is added to solution, the peptides 
cooperatively assemble with the aid of the Fe(III) porphyrin inside of the cage. 
Additionally, DLS can be used to analyze polydispersity of a sample. In Figure 
5.39, the DLS distribution revealed a mostly monomeric sample with little 
aggregation. It was important that in the two DLS distributions, the aggregation 
state did not change when the porphyrin was added (bottom part of the figure), 
also indicating that internal assembly occurred.  
  144 
The sizes of the peptides and porphyrin used in this work are feasible with the 
cavity size of the tetrahedron (approximately 7 nm diameter). The peptides are 
each 2.4 nm in length assuming that they do not form secondary structure 
elements, and the porphyrin’s diameter across the planar ring is approximately 1.5 
nm. However, due to the nature of the axial bis-histidine coordination of the 
metal, the planar ring diameter of the porphyrin will likely be oriented 
perpendicular to the length of the peptide. Additionally, the iron(III)-TPPS4 
porphyrin was used for these studies not only due to its water-soluble properties, 
but because of its negatively-charged sulfonato groups. The negative charges 
prevent electrostatic interactions from occurring between the negatively charged 
phosphate backbone of the DNA and the porphyrin side groups. The metal also 
aids in preventing undesired intercalation between the bases of the DNA because 
without histidine ligands, it can axially bind water molecules and thus avoid being 
planar enough to intercalate in the DNA. [77] Native gel electrophoresis and DLS 
experiments verified that no larger conformational changes of the 20T tetrahedron 
resulted following iron(III)-TPPS4 addition.  
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Figure 5.39. DLS measurements of the 20T-peptide and 20T-peptide-porphyrin 
complex each at a concentration of 10 µM of 20T-peptide and for the porphyrin 
sample, 5 µM porphyrin. The samples appear homogeneous, with very little 
aggregates.  
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Figure 5.40. 5% native gel electrophoresis comparing unpurified tetrahedron, 
purified tetrahedron-peptide, and purified tetrahedron-peptide-porphyrin, in order 
to test for the formation of aggregates during the porphyrin assembly. Lane "L" is 
10 µL of a low-molecular weight dsDNA ladder. For each of the other lanes, 18 
µL of sample was mixed with 2 µL of 10X native tracking dye (outlined in more 
detail in Materials and Methods). The native gel verifies the successful assembly 
of a porphyrin inside of the 20T tetrahedron. Since no size change of the 20T-
peptide construct occurs when the porphyrin is added to solution, the peptides 
cooperatively assemble with the aid of the Fe(III) porphyrin inside of the cage. 
The monomeric 20TP (20T-peptides) is shown in the band between 100-150bp on 
the lane labeled “Purified 10µM”. The monomeric 20T8P (20T-peptide-
porphyrin) is in the band between 100-150bp on the lane labeled “Purified 
10µM+5µM porphyrin”.   
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Challenges obtaining high concentration of sample 
Due to the modifications of one of the DNA strands in the porphyrin 
experiments, the yield of the entire preparation is typically no higher than 50 µM 
at a volume of ~150 µL. It is quite difficult to work with a sample of this quantity 
due to the fact that most EPR measurements require a sample concentration at 100 
µM or more and a volume of ~100 µL for X-band EPR. Scaling up the prep to 
anneal at a low concentration of 50 nM to minimize aggregates would not work 
with Scheme 2 (coupling porphyrin first), because this concentration is well 
below the experimental binding constant of 2 µM for the porphyrin-histidine 
coordination. Diluting the sample for annealing, as it is typically done for the 20T 
tetrahedron with no modifications, would cause the dissociation of the porphyrin 
from the ssDNA-peptide.  
 
 
 
EPR spectra of the fully-assembled tetrahedron-peptide-porphyrin complex 
In the EPR measurements with the peptide and porphyrin, a concentration 
in the 0.5-1 mM range was easily achievable (and clear EPR spectra are shown in 
Figures 5.36-5.37 with the concentration of unbound porphyrin remaining at 0.5 
mM for all of the tests. This is because there is significantly more material 
produced in a porphyrin or peptide synthesis than in a DNA purification. 
Therefore, due to the limitation in the concentration of the tetrahedron 
preparation, it was not possible to prepare a concentration ≥ 0.5 mM as in the 
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peptide-porphyrin measurements. Therefore, in Figure 5.41, the EPR spectra 
shows samples that contained only 5 µM of porphyrin for all the tests. For the 
EPR spectra of the 20T-peptide porphyrin sample the concentration is thereby 100 
times lower than the concentrations shown in the previous EPR spectra of 
porphyrin-peptide shown in Figures 5.36-5.37. It is very convincing that, despite 
the low concentration which lowers the signal-to-noise ratio, the CW EPR spectra 
shown in Figure 5.41 indicate g values at 6.4 matching those shown in the EPR 
spectra of the peptide and porphyrin. Therefore, the spectroscopic evidence 
suggests that the peptides are oriented inside of the tetrahedron and the terminal 
histidine residues are coordinating the Fe(III), causing the transition from high-
spin to low-spin Fe(III). Additionally, it is very exciting that the transition from 
high-spin to low-spin is even more pronounced when the peptides are 
incorporated inside the cage (green line in Figure 5.41) than when the same 
concentration of free peptides was added to the porphyrin. This indicates that both 
peptides are inside of the cage thereby providing the optimal coordination 
environment for the porphyrin.  
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Figure 5.41. EPR measurements of the fully-assembled tetrahedron-porphyrin 
complex, at 100X lower concentration than the previous measurements of the 
porphyrin-peptide.  
 
 
EPR measurements and optimization for low concentration of tetrahedron-
peptide-porphyrin complex 
Because of the obstacles associated with obtaining a high concentration of 
sample of the tetrahedron, the experimental parameters included varying the 
power applied to see if clearer spectra could be observed. The concentration of 
 
  150 
tetrahedron-peptide was 10 µM and the porphyrin was 5 µM for these 
experiments. Some of the lines at g =  3.03, 2.23, and 1.43 values were difficult to 
detect on the spectrum. Future experimental plans include scale-up of the 
preparation in order to improve the spectral resolution.  
 
UV-Vis measurements of 20TP8P assembled using Scheme 1 
As another proof of concept that the porphyrin was incorporated into the cage, the 
characteristic Soret shift was analyzed. As shown in Figure 5.42 below, the Soret 
shift was undetectable (only shifted ~1 nm) after assembling using Scheme 1, 
which involved assembling the 20TP first and then adding porphyrin. Although 
we initially thought that Scheme 1 would work, we realized that the optical 
spectroscopy was not detecting the incorporation properly.  
Figure 5.42. 20TP8P sample after annealing and assembling the complex 
according to Scheme 1 and then adding porphyrin. As seen, the Soret shift is 
barely visible as it is only red-shifted 1 nm.  
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Alternative strategy for porphyrin incorporation 
What is interesting to note is that initially the strategy for incorporating the 
porphyrin into the center of the tetrahedron was to introduce porphyrin into 
solution with the tetrahedron. In the course of this work, after the tetrahedron-
peptide complex was preassembled, it was discovered that the negatively-charged 
sulfonato groups are repulsed by the negatively-charged phosphate backbone of 
the DNA so that no porphyrin binding to the pre-assembled 20T tetrahedron can 
be observed. In this respect, the sulfonato groups help with preventing 
electrostatic interactions but they hindered the incorporation process after 
assembly of the 20TP complex. Therefore, a different technique was employed 
which involved coupling the porphyrin to the ssDNA-peptide conjugate first, and 
then annealing the other three strands of DNA to form the tetrahedron. This 
yielded not only a strong 8 nm Soret shift, as shown in Figure 5.42, but native gel 
electrophoresis also confirmed that the tetrahedron structure was formed. The 
annealing step consisted of 5-10 µM (rather than 50 nM as in the empty 
tetrahedron) and a small volume of ~50 µL (contrary to the ~450 mL annealing 
volume for the empty tetrahedron). These small volumes and higher 
concentrations were used to avoid overly diluting the sample and working below 
the Kd value for the reaction. Initially, the heating temperature of 70ºC was used 
to avoid damaging the porphyrin metal coordination. As shown in the native gel 
,because of the lower annealing temperature and higher concentration, larger 
amounts of aggregates of tetrahedra occurred, as expected. Later, the experiment 
was performed using the same conditions except 90°C annealing took place and 
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we discovered that no damage to the coordination occurred. In this case, native 
gel electrophoresis verified that less aggregates formed than with the 70°C 
annealing. The experiments shown with both the 70°C annealing and the 90°C 
annealing are shown below.  
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Figure 5.43. UV-Vis results after implementing Scheme 2 for the assembly of the 
20TP8P complex. The initial concern was that annealing temperatures of 90°C 
may damage the porphyrin coordination. Therefore, the annealing temperature 
used in these experiments was 70°C. The blue line is 5µM unbound porphyrin, the 
red line is 5µM porphyrin + 10 µM peptide, the yellow line is 5 µM porphyrin + 
10 µM ssDNA-peptide conjugate, and the green line is 5 µM porphyrin + 10 µM 
ssDNA with no peptides attached (as a control), and the purple line is 5 µM 
porphyrin + 10 µM of the 20TP8 complex after heating to 70°C for 10 minutes 
and cooling to room temperature. The results reveal that following annealing, 
Scheme 2 seems to provide the best route for assembling the 20TP8P complex, as 
the ssDNA-peptide is mixed with the porphyrin first, and the other strands are 
added. This procedure is done in a smaller volume but a higher concentration. The 
bottom spectra are a zoomed region showing the Soret shift.  
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Figure 5.44. After coupling the ssDNA to the porphyrin and then annealing using 
Scheme 2, the shift is observed. Soret shift is shown at the top, and Q band 
transitions at bottom. The yellow line is the ssDNA-peptide conjugate + 5 µM 
porphyrin before being mixed with the other strands and annealed at 90C, the blue 
line represents the assembled 20TP8P complex before heating (5 µM porphyrin + 
10 µM 20TP8), the red line is 5 µM of unbound porphyrin, the purple line is the 
ssDNA-peptide econjugate after annealing at 90°C (as a positive control), and the 
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green line is the entire 20TP8P complex after annealing at 90°C for 10 minutes 
and cooling to room temperature. These spectra indicate that the porphyrin 
coordination is not damaged by the 90°C temperature used for annealing. 
 
 
Although the Soret peak was visible in these UV-Vis experiments shown 
above, there was not a proper method established to separate aggregation products 
from the monomeric sample. This was especially of concern because in Scheme 2, 
the sample was annealed at a higher concentration than in Scheme 1, which 
typically resulted in more aggregation. A filtration method was established to first 
pass the annealed crude sample through a 30 kDa MWCO filter by centrifuging 
for 30 minutes at 13,000 rpm. The sample that remained on the top was applied to 
a 100kDa filter and centrifuged for 30 minutes at 13,000 rpm. The filtrate was 
removed and analyzed for a Soret peak. The top of the 30kDa MWCO filter is 
shown in Figure 5.45 which clearly shows that the reddish color is more intense at 
the top of the filter compared to the bottom (which contains unbound porphyrin 
and fragments). Additionally, a strong Soret shift is shown in Figure 5.46. The 
native gel also shows the fractions used in the filtration experiments.  
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Figure 5.45. Soret and Q band peaks of the isolated monomeric 20TP8P sample. 
The red circle of the native gel shows the monomeric tetrahedron isolated from all 
aggregates (the band on the far right). Some monomeric tetrahedron still remains 
in the top of the 100kDa filter, as shown in the lane second from the right. The 
Soret peak shown in the graph is of the monomeric tetrahedron only (corresponds 
to the lane in the gel). The color change at the photo at the top right shows 
unbound porphyrin which appears greener in color than the 20TP8P sample on the 
left, which is visibly reddish. The filter on the bottom right is after centrifuging 
the sample in the 30kDa MWCO filter during the first filtration step. The sample 
remaining in the top of that filter was placed into the top of a 100kDa MWCO 
filter for the next step.  
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Figure 5.46. A comparison of unbound porphyrin at a concentration of 5 µM to 
the fully assembled, isolated monomeric 20TP8P at a concentration of 10 µM 
20TP8 + 5 µM porphyrin. The Soret shift and the Q band transitions are clear in 
these spectra, which indicate that the internal coordination of the porphyrin is 
occurring.  
 
 
 
 
UV-Vis results of fully-assembled 20TP8P complex and challenges observing 
Soret shift 
As previously mentioned, the first method of porphyrin incorporation 
involved adding the porphyrin after the entire tetrahedron-peptide complex was 
annealed, purified, and concentrated. This resulted in no observable Soret shift, 
indicating that the porphyrin was not binding adequately inside of the cage. (See 
Figure 5.42). If any porphryin did successfully become incorporated inside of the 
cage, there was not enough incorporation to notice a Soret shift. (Other methods 
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had previously detected this incorporation such as EPR). An alternative strategy 
(Scheme 2) was used where the porphyrin was first coupled to the ssDNA-peptide 
and then annealed in a higher concentration and small volume. Under these 
conditions, a shift was observed, from 408 to 417 nm. This hyperchromic Soret 
shift detects the formation of the bis-histidine hexacoordinated species. (A 
pentacoordinated species would result in a red-shift but a decreased peak 
intensity.) Figures 5.45-5.46 above clearly illustrate the feasibility of Scheme 2 
compared to Scheme 1.  
 
Crystallization of fully-assembled complex 
Crystallization trials of the fully-assembled tetrahedron-peptide-porphyrin 
complex were conducted. The conditions used were the same as for the 20T 
tetrahedron – 20T Fine Screen 4 was used. Crystals grew in approximately 2 days. 
Figure 5.47 shows some images of the crystals. 
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Figure 5.47. Crystals of the 20T-peptide and 20T-peptide-porphyrin structures. 
Crystals grew in approximately 3 days.  
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Figure 5.48. Single diffraction pattern of 20T-peptide-porphyrin crystals. These 
crystals are more tolerant to longer x-ray exposure times than the tetrahedron 
crystals.  
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6. CONCLUSION AND OUTLOOK  
In this work, the conjugation of the tetrahedron with internally assembled 
peptides and porphyrins has been achieved. The same design could be applied in 
future constructs using the peptides based on PSII and assembly of the metal 
cluster. This requires the synthesis of the remaining two peptide sequences 
described in the proposed complex in Figure 2.3 and conjugating them to four 
additional sites within the tetrahedron. This would be very challenging as it would 
require use of up to five different coupling chemistries to be employed. An 
alternate strategy would employ the use of a cyclic peptide that would have all of 
the critical amino acids that provide ligands to the manganese cluster, and 
conjugate it to only one or two bases in the tetrahedron instead of the previously 
proposed five sites. This would drastically simplify the coupling challenge as only 
one conjugation to the tetrahedron would be necessary. The cyclic peptide design 
is currently underway.  
In another strategy, PNA-peptides could be used to hybridize with the 
DNA (work of Justin Flory), which does not require chemical conjugation directly 
to the DNA. In this strategy, the PNA hybridizes to the DNA and the peptide is 
already co-synthesized with the PNA. This technique could be combined with the 
chemical conjugation strategy described in this work to incorporate all of the 
peptide sequences inside of the cage. 
A different alternative strategy would include the use of high-valent 
manganese porphyrins as catalysts for water oxidation. This strategy is very 
interesting as it could use the same method developed in this work for the iron 
  162 
porphyrins with the goal of observing water oxidation further down the road. In 
any case, the results described with iron porphyrin encapculation can be further 
used to facilitate the re-designing of the water oxidation complex in PSII. In order 
to improve the diffraction quality of the crystals, techniques may be used in the 
future to remove aggregates from solution that may hinder the formation of 
higher-quality crystals. Additionally, a stable single-stranded DNA design would 
have the potential to deliver promising results and could maybe be used as a 
template or as a film to organize redox-active proteins and photo-excitable 
pigments. 
 Lastly, other metals can be incorporated into the macrocycle of other 
porphyrins so that different spectroscopic techniques can be employed, such as 
fluorescence. Different metals can be selected based on their excited state 
lifetimes so other spectroscopy can be used. As a functional strategy for the 
Fe(III) porphyrins described in this work, a reducing agent such as dithionite or 
ascorbate can be added to see if the agent can migrate into the cage, reducing the 
Fe(III) to Fe(II). The Soret band and Q bands would verify this reduction of the 
iron.  
 Electrochemical techniques are also in the pipeline, as the ultimate goal is 
to show the complex’s redox properties. A scale-up of the experiment is 
underway which would provide a concentrated sample for electrochemical 
measurements. Electrochemistry would also verify the oxidation state of the iron 
after reduction.    
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APPENDIX A  
20T FINE SCREEN 1 
EXAMPLES OF FINE SCREEN SOLUTIONS USED IN 20T TETRAHEDRON 
CRYSTALLIZATION EXPERIMENTS 
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20T	  Fine	  Screen	  1	  –	  10	  mL	  screen	  solutions 
50	  mM	  sodium	  cacodylate	  pH	  6.0,	  20	  mM	  L-­‐argininamide,	  30%	  PEG	  1000	  
Stock	  solutions:	  
1. 1M	  sodium	  cacodylate	  pH	  6.0	  
2. 1M	  L-­‐argininamide	  
3. 50%	  PEG	  1000	  
	  
	  
	  
	  
	  
	  
33%	  PEG	  
1000	  
34%	  PEG	  
1000	  
35%	  PEG	  
1000	  
36%	  PEG	  
1000	  
37%	  PEG	  
1000	  
38%	  PEG	  
1000	  
	  
10mM	  
argininamide	  
.5	  mL	  of	  
cacodylate	  	  
.1	  mL	  
argininamide	  
6.6	  mL	  33%	  
PEG	  1000	  
2.8	  mL	  H2O	  
.5	  mL	  
.1	  mL,	  
6.8	  mL	  	  
2.60	  mL	  	  
.5	  mL	  
.1	  mL	  	  
7	  mL	  
2.40	  mL	  
.5	  mL	  
	  .1	  mL	  
7.2	  mL	  
2.20	  mL	  
.5	  mL	  
.1	  mL	  
7.4	  mL	  
2.0	  mL	  
.5	  mL	  
.1	  mL	  
7.6	  mL	  
1.80	  mL	  
15mM	  
argininamide	  
.5	  mL	  of	  
cacodylate	  	  
.15	  mL	  
argininamide	  
6.6	  mL	  33%	  
PEG	  1000	  
2.75	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  	  
.15	  mL	  	  
7	  mL	  
2.	  35	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.4	  mL	  
1.95	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
20mM	  
argininamide	  
.5	  mL	  of	  
cacodylate	  
.2	  mL	  
argininamide	  
6.6	  mL	  33%	  
PEG	  1000	  
2.7	  mL	  H2O	  
.5	  mL,	  
.2	  mL	  
6.8	  mL	  
2.5	  mL	  
.5	  mL	  
.2	  mL	  
7mL	  
	  2.3	  mL	  	  
.5	  mL	  
.2	  mL	  
7.2	  mL	  
2.1	  mL	  
.5	  mL	  
.2	  mL	  
7.4	  mL	  
1.9	  mL	  
.5	  mL	  
.2	  mL	  
7.6	  mL	  
1.7	  mL	  
25mM	  
argininamide	  
.5	  mL	  of	  
cacodylate	  	  
.25	  mL	  
argininamide	  
6.6	  mL	  33%	  
PEG	  1000	  	  
2.65	  mL	  H2O	  
.5	  mL	  	  
.25	  mL	  
6.8	  mL	  
2.45	  mL	  
.5	  mL	  	  
	  .25	  mL	  	  
7	  mL	  
2.25	  mL	  
.5	  mL	  
.25	  mL	  
7.2	  mL	  
2.05	  mL	  
.5	  mL	  
.25	  mL	  
7.4	  mL	  
1.85	  mL	  
.5	  mL	  
.25	  mL	  
7.6	  mL	  
1.65	  mL	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20T	  Fine	  Screen	  2	  	  -­‐	  10	  mL	  screen	  solutions	  	  
50	  mM	  sodium	  cacodylate	  pH	  6.0,	  20	  mM	  L-­‐argininamide,	  30%	  PEG	  1000	  
Stock	  solutions:	  
1.	   1M	  sodium	  cacodylate	  pH	  6.0	  
2.	   1M	  L-­‐argininamide	  
3.	   50%	  PEG	  1000	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
	  
23%	  PEG	  
1000	  
24%	  PEG	  
1000	  
25%	  PEG	  
1000	  
26%	  PEG	  
1000	  
27%	  PEG	  
1000	  
28%	  PEG	  
1000	  
	  
	  
argininamide	  
10mM	  
.5	  mL	  of	  
cacodylate	  	  
.1	  mL	  
argininamide	  
4.6	  mL	  28%	  
PEG	  1000	  
4.8	  mL	  H2O	  
.5	  mL	  
.1	  mL	  
4.8	  mL	  	  
4.60	  mL	  	  
.5	  mL	  
.1	  mL	  	  
5	  mL	  
4.40	  mL	  
.5	  mL	  
	  .1	  mL	  
5.2	  mL	  
4.20	  mL	  
.5	  mL	  
.1	  mL	  
5.4	  mL	  
4.00	  mL	  
.5	  mL	  
.1	  mL	  
5.6	  mL	  
3.80	  mL	  
argininamide	  
15mM	  
.5	  mL	  of	  
cacodylate	  	  
.15	  mL	  
argininamide	  
4.6	  mL	  28%	  
PEG	  1000	  	  
4.75	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  	  
.15	  mL	  	  
5	  mL	  
4.35	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.4	  mL	  
3.95	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
argininamide	  
20mM	  
.5	  mL	  of	  
cacodylate	  
.2	  mL	  
argininamide	  
4.6	  mL	  28%	  
PEG	  1000	  
4.7	  mL	  H2O	  
.5	  mL,	  
.2	  mL	  
4.8	  mL	  
4.50	  mL	  
.5	  mL	  
.2	  mL	  
5	  mL	  
	  4.30	  mL	  	  
.5	  mL	  
.2	  mL	  
5.2	  mL	  
4.10	  mL	  
.5	  mL	  
.2	  mL	  
5.4	  mL	  
3.90	  mL	  
.5	  mL	  
.2	  mL	  
5.6	  mL	  
3.70	  mL	  
argininamide	  
25	  mM	  
.5	  mL	  of	  
cacodylate	  	  
.25	  mL	  
argininamide	  
4.6	  mL	  28%	  
PEG	  1000	  	  
4.65	  mL	  H2O	  
.5	  mL	  	  
.25	  mL	  
4.8	  mL	  
4.45	  mL	  
.5	  mL	  	  
	  .25	  mL	  	  
5	  mL	  
4.25	  mL	  
.5	  mL	  
.25	  mL	  
5.2	  mL	  
4.05	  mL	  
.5	  mL	  
.25	  mL	  
5.4	  mL	  
3.85	  mL	  
.5	  mL	  
.25	  mL	  
5.6	  mL	  
3.65	  mL	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H11	  Screen	  3	  	  -­‐	  10	  mL	  screen	  solutions	  	  
H11	  -­‐	  50	  mM	  sodium	  cacodylate	  pH	  6.0,	  20	  mM	  L-­‐argininamide,	  30%	  PEG	  1000	  
	  
	  
Stock	  solutions:	  
1. 1M	  sodium	  cacodylate	  pH	  6.0	  
2. 1M	  L-­‐argininamide	  
3. 50%	  PEG	  1000	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
	  
28%	  PEG	  
1000	  
30%	  PEG	  
1000	  
32%	  PEG	  
1000	  
34%	  PEG	  
1000	  
36%	  PEG	  
1000	  
38%	  PEG	  
1000	  
	  
	  
argininamide	  
10mM	  
.5	  mL	  of	  
cacodylate	  	  
.1	  mL	  
argininamide	  
5.6	  mL	  28%	  
PEG	  1000	  
3.8	  mL	  H2O	  
.5	  mL	  
.1	  mL	  
6	  mL	  	  
3.4	  mL	  	  
.5	  mL	  
.1	  mL	  	  
6.4	  mL	  
3	  mL	  
.5	  mL	  
	  .1	  mL	  
6.8	  mL	  
2.6	  mL	  
.5	  mL	  
.1	  mL	  
7.2	  mL	  
2.2	  mL	  
.5	  mL	  
.1	  mL	  
7.6	  mL	  
1.8	  mL	  
argininamide	  
15mM	  
.5	  mL	  of	  
cacodylate	  	  
.15	  mL	  
argininamide	  
5.6	  mL	  28%	  
PEG	  1000	  	  
3.75	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6	  mL	  
3.35	  mL	  
.5	  mL	  	  
.15	  mL	  	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
argininamide	  
20mM	  
.5	  mL	  of	  
cacodylate	  
.2	  mL	  
argininamide	  
5.6	  mL	  28%	  
PEG	  1000	  
3.7	  mL	  H2O	  
.5	  mL,	  
.2	  mL	  
6	  mL	  
3.3	  mL	  
.5	  mL	  
.2	  mL	  
6.4	  mL	  
	  2.9	  mL	  	  
.5	  mL	  
.2	  mL	  
6.8	  mL	  
2.5	  mL	  
.5	  mL	  
.2	  mL	  
7.2	  mL	  
2.1	  mL	  
.5	  mL	  
.2	  mL	  
7.6	  mL	  
1.7	  mL	  
argininamide	  
25	  mM	  
.5	  mL	  of	  
cacodylate	  	  
.25	  mL	  
argininamide	  
5.6	  mL	  28%	  
PEG	  1000	  	  
3.65	  mL	  H2O	  
.5	  mL	  	  
.25	  mL	  
6	  mL	  
3.25	  mL	  
.5	  mL	  	  
	  .25	  mL	  	  
6.4	  mL	  
2.85	  mL	  
.5	  mL	  
.25	  mL	  
6.8	  mL	  
2.45	  mL	  
.5	  mL	  
.25	  mL	  
7.2	  mL	  
2.05	  mL	  
.5	  mL	  
.25	  mL	  
7.6	  mL	  
1.65	  mL	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  177 
 
 
20T	  Fine	  Screen	  4	  –	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  Cacodylate	  pH	  6.0,	  1M	  
Argininamide,	  29-­‐34%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  sodium	  cadodylate	  pH	  6.0	  
2.	   1M	  L-­‐argininamide	  
	  	  	  	  	  	  	  	  	  3.	  	  	  	  	  50%	  PEG	  1000	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
29%	  PEG	  
1000	  
30%	  PEG	  
1000	  
31%	  PEG	  
1000	  
32%	  PEG	  
1000	  
33%	  PEG	  
1000	  
34%	  PEG	  
1000	  
	  
	  
argininamide	  
10mM	  
.5	  mL	  of	  
cacodylate	  	  
.1	  mL	  
argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  
3.6	  mL	  H2O	  
.5	  mL	  
.1	  mL	  
6.0	  mL	  	  
3.4	  mL	  	  
.5	  mL	  
.1	  mL	  	  
6.2	  mL	  
3.2	  mL	  
.5	  mL	  
	  .1	  mL	  
6.4	  mL	  
3	  mL	  
.5	  mL	  
.1	  mL	  
6.6	  mL	  
2.8	  mL	  
.5	  mL	  
.1	  mL	  
6.8	  mL	  
2.6	  mL	  
argininamide	  
15mM	  
.5	  mL	  of	  
cacodylate	  	  
.15	  mL	  
argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.55	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  	  
.15	  mL	  	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
2.55	  mL	  
argininamide	  
20mM	  
.5	  mL	  of	  
cacodylate	  
.2	  mL	  
argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  
3.5	  mL	  H2O	  
.5	  mL,	  
.2	  mL	  
6.0	  mL	  
3.3	  mL	  
.5	  mL	  
.2	  mL	  
6.2	  mL	  
	  3.1	  mL	  	  
.5	  mL	  
.2	  mL	  
6.4	  mL	  
2.9	  mL	  
.5	  mL	  
.2	  mL	  
6.6	  mL	  
2.7	  mL	  
.5	  mL	  
.2	  mL	  
6.8	  mL	  
2.5	  mL	  
argininamide	  
25mM	  
.5	  mL	  of	  
cacodylate	  	  
.25	  mL	  
argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.45	  mL	  H2O	  
.5	  mL	  	  
.25	  mL	  
6.0	  mL	  
3.25	  mL	  
.5	  mL	  	  
	  .25	  mL	  	  
6.2	  mL	  
3.05	  mL	  
.5	  mL	  
.25	  mL	  
6.4	  mL	  
2.85	  mL	  
.5	  mL	  
.25	  mL	  
6.6	  mL	  
2.65	  mL	  
.5	  mL	  
.25	  mL	  
6.8	  mL	  
2.45	  mL	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20T	  Fine	  Screen	  5a	  (TRIS)-­‐	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  MES	  pH	  6.0,	  50	  mM	  
Tris	  pH	  7.0,	  50	  mM	  Tris	  pH	  8.0,	  50	  mM	  Tris	  pH	  9.0,	  15	  mM	  Argininamide,	  18-­‐28%	  
PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  MES	  pH	  6.0	  
2.	   0.5M	  Tris	  pH	  7.0	  
3.	   0.5M	  Tris	  pH	  8.0	  
4.	   0.5M	  Tris	  pH	  9.0	  
5.	   1M	  Argininamide	  
	  	  	  	  	  	  	  6.	   50%	  PEG	  1000	  
	  
	  
	  
18%	  PEG	  
1000	  
20%	  PEG	  
1000	  
22%	  PEG	  
1000	  
24%	  PEG	  
1000	  
26%	  PEG	  
1000	  
28%	  PEG	  
1000	  
	  
	  
MES	  pH	  6.0	  
50mM	  
.5	  mL	  of	  MES	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  
5.75	  mL	  H2O	  
.5	  mL	  
.15	  mL	  
4.0	  mL	  	  
5.35	  mL	  	  
.5	  mL	  
.15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
	  .15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  7.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  7.0	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  	  
5.75	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  	  
.15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  8.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  8.0	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  
5.75	  mL	  H2O	  
.5	  mL,	  
.15	  mL	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  
.15	  mL	  
4.4	  mL	  
	  4.95	  mL	  	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  9.0	  50	  
mM	  
.5	  mL	  of	  Tris	  
pH	  9.0	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  	  
5.75	  mL	  H2O	  
.5	  mL	  	  
.15	  mL	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  	  
	  .15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	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20T	  Fine	  Screen	  5b	  (TRIS)-­‐	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  MES	  pH	  6.0,	  50	  mM	  
Tris	  pH	  7.0,	  50	  mM	  Tris	  pH	  8.0,	  50	  mM	  Tris	  pH	  9.0,	  15	  mM	  Argininamide,	  30-­‐40%	  
PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  MES	  pH	  6.0	  
2.	   0.5M	  Tris	  pH	  7.0	  
3.	   0.5M	  Tris	  pH	  8.0	  
4.	   0.5M	  Tris	  pH	  9.0	  
5.	   1M	  L-­‐argininamide	  
	  	  	  	  	  	  	  6.	   50%	  PEG	  1000	  
	  
	  
	  
	  
	  
	  
 
 
 
 
 
 
 
	  
30%	  PEG	  
1000	  
32%	  PEG	  
1000	  
34%	  PEG	  
1000	  
36%	  PEG	  
1000	  
38%	  PEG	  
1000	  
40%	  PEG	  
1000	  
	  
	  
MES	  pH	  6.0	  
50mM	  
.5	  mL	  of	  MES	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  
3.35	  mL	  H2O	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  	  
2.95	  mL	  	  
.5	  mL	  
.15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
	  .15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
8.0	  mL	  
1.35	  mL	  
Tris	  pH	  7.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  7.0	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  	  
3.35	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  	  
.15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  8.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  8.0	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  
3.35	  mL	  H2O	  
.5	  mL,	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
	  2.55	  mL	  	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  9.0	  50	  
mM	  
.5	  mL	  of	  Tris	  
pH	  9.0	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  	  
3.35	  mL	  H2O	  
.5	  mL	  	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  	  
	  .15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	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20T	  Fine	  Screen	  6a	  (TRIS	  +	  cacodylate)-­‐	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  MES	  +	  
50	  mM	  Cacodylate	  pH	  6.0,	  50	  mM	  Tris	  +	  50	  mM	  Cacodylate	  pH	  7.0,	  50	  mM	  Tris	  +	  
50mM	  Cacodylate	  pH	  8.0,	  50	  mM	  Tris	  +	  50mM	  Cacodylate	  pH	  9.0,	  15	  mM	  
Argininamide,	  18-­‐28%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  MES	  +	  0.5M	  Cacodylate	  pH	  6.0	  	  	  
2.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  7.0	  
4. 0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  8.0	  
5. 0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  9.0	  
6. 1M	  Argininamide	  
7. 50%	  PEG	  1000	  
	  
	  
18%	  PEG	  
1000	  
20%	  PEG	  
1000	  
22%	  PEG	  
1000	  
24%	  PEG	  
1000	  
26%	  PEG	  
1000	  
28%	  PEG	  
1000	  
	  
	  
MES	  +	  
Cacodylate	  
pH	  6.0	  
50mM	  
.5	  mL	  of	  MES	  
+	  Caco	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  
5.75	  mL	  H2O	  
.5	  mL	  
.15	  mL	  
4.0	  mL	  	  
5.35	  mL	  	  
.5	  mL	  
.15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
	  .15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  +	  
Cacodylate	  
pH	  7.0	  
50mM	  
.5	  mL	  of	  Tris	  
+	  Caco	  pH	  
7.0	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  	  
5.75	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  	  
.15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  +	  
Cacodylate	  
pH	  8.0	  
50mM	  
.5	  mL	  of	  Tris	  
+	  Caco	  pH	  
8.0	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  
5.75	  mL	  H2O	  
.5	  mL,	  
.15	  mL	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  
.15	  mL	  
4.4	  mL	  
	  4.95	  mL	  	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  +	  
Cacodylate	  
pH	  9.0	  
50mM	  
.5	  mL	  of	  Tris	  
+	  Caco	  pH	  
9.0	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  	  
5.75	  mL	  H2O	  
.5	  mL	  	  
.15	  mL	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  	  
	  .15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
	  
 
 
 
 
  184 
APPENDIX H 
 
20T FINE SCREEN 6b 
	  
  185 
	  
	  
	  
	  
20T	  Fine	  Screen	  6b	  (TRIS	  +	  Cacodylate)-­‐	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  MES	  +	  
50mM	  Cacodylate	  pH	  6.0,	  50	  mM	  Tris	  +	  50mM	  Cacodylate	  pH	  7.0,	  50	  mM	  Tris	  +	  
50mM	  Cacodylate	  pH	  8.0,	  50	  mM	  Tris	  +	  50mM	  Cacodylate	  pH	  9.0,	  15	  mM	  
Argininamide,	  30-­‐40%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  MES	  +	  0.5M	  Cacodylate	  pH	  6.0	  
2.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  7.0	  
3.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  8.0	  
4.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  9.0	  
5.	   1M	  Argininamide	  
	  	  	  	  	  	  	  6.	   50%	  PEG	  1000	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
	  
30%	  PEG	  
1000	  
32%	  PEG	  
1000	  
34%	  PEG	  
1000	  
36%	  PEG	  
1000	  
38%	  PEG	  
1000	  
40%	  PEG	  
1000	  
	  
	  
MES	  +	  
Cacodylate	  
pH	  6.0	  
50mM	  
.5	  mL	  of	  MES	  
+	  Caco	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  
3.35	  mL	  H2O	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  	  
2.95	  mL	  	  
.5	  mL	  
.15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
	  .15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
8.0	  mL	  
1.35	  mL	  
Tris	  +	  
Cacodylate	  
pH	  7.0	  
50mM	  
.5	  mL	  of	  Tris	  
+	  Caco	  pH	  
7.0	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  	  
3.35	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  	  
.15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  +	  
Cacodylate	  
pH	  8.0	  
50mM	  
.5	  mL	  of	  Tris	  
+	  Caco	  pH	  
8.0	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  
3.35	  mL	  H2O	  
.5	  mL,	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
	  2.55	  mL	  	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  +	  
Cacodylate	  
pH	  9.0	  50	  
mM	  
.5	  mL	  of	  Tris	  
+	  Caco	  pH	  
9.0	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  	  
3.35	  mL	  H2O	  
.5	  mL	  	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  	  
	  .15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	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20T	  Fine	  Screen	  7a	  (New	  Buffers)-­‐	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  MES	  pH	  6.0,	  
50	  mM	  HEPES	  pH	  7.0,	  50	  mM	  Tris	  pH	  8.0,	  50	  mM	  Tris	  pH	  9.0,	  15	  mM	  
Argininamide,	  18-­‐28%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  MES	  pH	  6.0	  
2.	   0.5M	  HEPES	  pH	  7.0	  
3.	   0.5M	  Tris	  pH	  8.0	  
4.	   0.5M	  Tris	  pH	  9.0	  
5.	   1M	  Argininamide	  
	  	  	  	  	  	  6.	   50%	  PEG	  1000	  
	  
	   18%	  PEG	  1000	   20%	  PEG	  1000	   22%	  PEG	  1000	   24%	  PEG	  1000	   26%	  PEG	  1000	   28%	  PEG	  1000	  
	  
	  
MES	  pH	  6.0	  
50mM	  
.5	  mL	  of	  MES	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  
5.75	  mL	  H2O	  
.5	  mL	  
.15	  mL	  
4.0	  mL	  	  
5.35	  mL	  	  
.5	  mL	  
.15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
	  .15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
HEPES	  pH	  7.0	  
50mM	  
.5	  mL	  of	  
HEPES	  pH	  7.0	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  	  
5.75	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  	  
.15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  8.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  8.0	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  
5.75	  mL	  H2O	  
.5	  mL,	  
.15	  mL	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  
.15	  mL	  
4.4	  mL	  
	  4.95	  mL	  	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  9.0	  50	  
mM	  
.5	  mL	  of	  Tris	  
pH	  9.0	  	  
.15	  mL	  
Argininamide	  
3.6	  mL	  50%	  
PEG	  1000	  	  
5.75	  mL	  H2O	  
.5	  mL	  	  
.15	  mL	  
4.0	  mL	  
5.35	  mL	  
.5	  mL	  	  
	  .15	  mL	  	  
4.4	  mL	  
4.95	  mL	  
.5	  mL	  
.15	  mL	  
4.8	  mL	  
4.55	  mL	  
.5	  mL	  
.15	  mL	  
5.2	  mL	  
4.15	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	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20T	  Fine	  Screen	  7b	  (New	  Buffers)-­‐	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  MES	  pH	  6.0,	  
50	  mM	  HEPES	  pH	  7.0,	  50	  mM	  Tris	  pH	  8.0,	  50	  mM	  Tris	  pH	  9.0,	  15	  mM	  
Argininamide,	  30-­‐40%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  MES	  pH	  6.0	  
2.	   0.5M	  HEPES	  pH	  7.0	  
3.	   0.5M	  Tris	  pH	  8.0	  
4.	   0.5M	  Tris	  pH	  9.0	  
5.	   1M	  Argininamide	  
	  	  	  	  	  	  6.	   50%	  PEG	  1000	  
	  
	  
30%	  PEG	  
1000	  
32%	  PEG	  
1000	  
34%	  PEG	  
1000	  
36%	  PEG	  
1000	  
38%	  PEG	  
1000	  
40%	  PEG	  
1000	  
	  
	  
MES	  pH	  6.0	  
50mM	  
.5	  mL	  of	  MES	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  
3.35	  mL	  H2O	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  	  
2.95	  mL	  	  
.5	  mL	  
.15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
	  .15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
8.0	  mL	  
1.35	  mL	  
Tris	  pH	  7.0	  
50mM	  
.5	  mL	  of	  
HEPES	  pH	  7.0	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  	  
3.35	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  	  
.15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  8.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  8.0	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  
3.35	  mL	  H2O	  
.5	  mL,	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
	  2.55	  mL	  	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	  
Tris	  pH	  9.0	  50	  
mM	  
.5	  mL	  of	  Tris	  
pH	  9.0	  	  
.15	  mL	  
Argininamide	  
6.0	  mL	  50%	  
PEG	  1000	  	  
3.35	  mL	  H2O	  
.5	  mL	  	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  	  
	  .15	  mL	  	  
6.8	  mL	  
2.55	  mL	  
.5	  mL	  
.15	  mL	  
7.2	  mL	  
2.15	  mL	  
.5	  mL	  
.15	  mL	  
7.6	  mL	  
1.75	  mL	  
.5	  mL	  
.15	  mL	  
5.6	  mL	  
3.75	  mL	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20T	  Fine	  Screen	  8	  -­‐	  New	  Salts	  +	  different	  pHs	  (NO	  ARGININAMIDE—ONLY	  
Mg(Ac)2	  –	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  Tris	  pH	  7.0,	  50mM	  Tris	  pH	  9.0,	  50mM	  
Tris	  +	  50mM	  Cacodylate	  pH	  7.0,	  50mM	  Tris	  +	  50mM	  Cacodylate	  pH	  9.0,	  15	  mM	  
Mg(Ac)2	  ,	  29-­‐34%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  Tris	  pH	  7.0	  
2.	   0.5M	  Tris	  pH	  9.0	  
3.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  7.0	  
4.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  9.0	  
5.	   1M	  Magnesium	  acetate	  
6.	   50%	  PEG	  1000	  
	  
	  
	  
	  
	  
 
 
 
 
	  
29%	  PEG	  
1000	  
30%	  PEG	  
1000	  
31%	  PEG	  
1000	  
32%	  PEG	  
1000	  
33%	  PEG	  
1000	  
34%	  PEG	  
1000	  
	  
	  
Tris	  pH	  7.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  7.0	  	  
.15	  mL	  
Mg(Ac)2	  
5.8	  mL	  50%	  
PEG	  1000	  
3.55	  mL	  H2O	  
.5	  mL	  
.15	  mL	  
6.0	  mL	  	  
3.35	  mL	  	  
.5	  mL	  
.15	  mL	  	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
	  .15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
2.55	  mL	  
Tris	  pH	  9.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  9.0	  	  
.15	  mL	  
Mg(Ac)2	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.55	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  	  
.15	  mL	  	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
2.55	  mL	  
Tris	  +	  
Cacodylate	  pH	  
7.0	  50mM	  
.5	  mL	  of	  Tris	  +	  
Caco	  pH	  7.0	  
.15	  mL	  
Mg(Ac)2	  
5.8	  mL	  50%	  
PEG	  1000	  
3.55	  mL	  H2O	  
.5	  mL,	  
.15	  mL	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  
.15	  mL	  
6.2	  mL	  
	  3.15	  mL	  	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
2.55	  mL	  
Tris	  +	  
Cacodylate	  pH	  
9.0	  50	  mM	  
.5	  mL	  of	  Tris	  +	  
Caco	  pH	  9.0	  	  
.15	  mL	  
Mg(Ac)2	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.55	  mL	  H2O	  
.5	  mL	  	  
.15	  mL	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  	  
	  .15	  mL	  	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
2.55	  mL	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20T	  Fine	  Screen	  9	  -­‐	  New	  Salts	  +	  different	  pHs	  (50%	  ARGININAMIDE	  +	  50%	  
Mg(Ac)2)	  –	  10	  mL	  screen	  solutions	  -­‐	  	  50	  mM	  Tris	  pH	  7.0,	  50mM	  Tris	  pH	  9.0,	  
50mM	  Tris	  +	  50mM	  Cacodylate	  pH	  7.0,	  50mM	  Tris	  +	  50mM	  Cacodylate	  pH	  9.0,	  
7.5	  mM	  Mg(Ac)2	  ,	  7.5	  mM	  Argininamide,	  29-­‐34%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  Tris	  pH	  7.0	  
2.	   0.5M	  Tris	  pH	  9.0	  
3.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  7.0	  
4.	   0.5M	  Tris	  +	  0.5M	  Cacodylate	  pH	  9.0	  
5.	   1M	  Magnesium	  acetate	  
6.	   1M	  L-­‐Argininamide	  
7.	   50%	  PEG	  1000	  
	  
	  
	  
	  
	  
 
 
	   29%	  PEG	  1000	  
30%	  PEG	  
1000	  
31%	  PEG	  
1000	  
32%	  PEG	  
1000	  
33%	  PEG	  
1000	  
34%	  PEG	  
1000	  
	  
	  
5mM	  
Argininamide	  
+	  
5mM	  Mg(Ac)2	  
.5	  mL	  of	  Na-­‐
caco	  pH	  6.0	  	  
.05	  mL	  
Mg(Ac)2	  
.05	  mL	  
Argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  
3.6	  mL	  H2O	  
.5	  mL	  
.05	  mL	  
.05	  mL	  
6.0	  mL	  	  
3.4	  mL	  	  
.5	  mL	  
.05	  mL	  	  
.05	  mL	  
6.2	  mL	  
3.2	  mL	  
.5	  mL	  
	  .05	  mL	  
.05	  mL	  
6.4	  mL	  
3.0	  mL	  
.5	  mL	  
.05	  mL	  
.05	  mL	  
6.6	  mL	  
2.8	  mL	  
.5	  mL	  
.05	  mL	  
.05	  mL	  
6.8	  mL	  
2.6	  mL	  
15mM	  
Mg(Ac)2	  
.5	  mL	  of	  Na-­‐
caco	  pH	  6.0	  	  
.15	  mL	  
Mg(Ac)2	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.55	  mL	  H2O	  
.5	  mL	  	  
	  .15	  mL	  	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  	  
.15	  mL	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
.15	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.15	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.15	  mL	  
6.8	  mL	  
2.55	  mL	  
10mM	  
Argininamide	  
+	  
10mM	  
Mg(Ac)2	  
.5	  mL	  of	  Na-­‐
caco	  pH	  6.0	  
.1	  mL	  Mg(Ac)2	  
.1	  mL	  
Argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  
3.5	  mL	  H2O	  
.5	  mL,	  
.1	  mL	  
.1	  mL	  
6.0	  mL	  
3.3	  mL	  
.5	  mL	  
.1	  mL	  
.1	  mL	  
6.2	  mL	  
	  3.1	  mL	  	  
.5	  mL	  
.1	  mL	  
.1	  mL	  
6.4	  mL	  
2.9	  mL	  
.5	  mL	  
.1	  mL	  
.1	  mL	  
6.6	  mL	  
2.7	  mL	  
.5	  mL	  
.1	  mL	  
.1	  mL	  
6.8	  mL	  
2.5	  mL	  
25mM	  
Mg(Ac)2	  
.5	  mL	  of	  Na-­‐
caco	  pH	  6.0	  	  
.25	  mL	  
Mg(Ac)2	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.45	  mL	  H2O	  
.5	  mL	  	  
.25	  mL	  
6.0	  mL	  
3.25	  mL	  
.5	  mL	  	  
	  .25	  mL	  	  
6.2	  mL	  
3.05	  mL	  
.5	  mL	  
.25	  mL	  
6.4	  mL	  
2.85	  mL	  
.5	  mL	  
.25	  mL	  
6.6	  mL	  
2.65	  mL	  
.5	  mL	  
.25	  mL	  
6.8	  mL	  
2.45	  mL	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20T	  Fine	  Screen	  10	  	  -­‐	  New	  Salts	  +	  old	  conditions	  of	  Screen	  4	  (Argininamide	  +	  	  
Mg(Ac)2	  as	  salts)	  –	  10	  mL	  screen	  solutions	  -­‐	  50	  mM	  Na-­‐cacodylate	  pH	  6.0,	  
varying	  [	  ]	  of	  Mg(Ac)2	  and	  Argininamide,	  29-­‐34%	  PEG	  1000	  
Stock	  solutions:	  
1.	   0.5M	  Sodium	  cacodylate	  pH	  6.0	  (buffer)	  
2.	   1M	  Magnesium	  acetate	  (salt)	  
3.	   1M	  L-­‐Argininamide	  (salt)	  	  
	  	  	  	  	  	  	  4.	   50%	  PEG	  1000	  (ppt)	  
	  
	  
	  
 
 
 
 
 
	   29%	  PEG	  1000	   30%	  PEG	  1000	   31%	  PEG	  1000	   32%	  PEG	  1000	   33%	  PEG	  1000	   34%	  PEG	  1000	  
	  
	  
Tris	  pH	  7.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  7.0	  	  
.075	  mL	  
Mg(Ac)2	  
.075	  mL	  
Argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  
3.55	  mL	  H2O	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.0	  mL	  	  
3.35	  mL	  	  
.5	  mL	  
.075	  mL	  	  
.075	  mL	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
	  .075	  mL	  
.075	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.8	  mL	  
2.55	  mL	  
Tris	  pH	  9.0	  
50mM	  
.5	  mL	  of	  Tris	  
pH	  9.0	  	  
.075	  mL	  
Mg(Ac)2	  
.075	  mL	  
Argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.55	  mL	  H2O	  
.5	  mL	  	  
	  .075	  mL	  
.075	  mL	  	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  	  
.075	  mL	  	  
.075	  mL	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.8	  mL	  
2.55	  mL	  
Tris	  +	  
Cacodylate	  pH	  
7.0	  50mM	  
.5	  mL	  of	  Tris	  +	  
Caco	  pH	  7.0	  
.075	  mL	  
Mg(Ac)2	  
.075	  mL	  
Argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  
3.55	  mL	  H2O	  
.5	  mL,	  
.075	  mL	  
.075	  mL	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.2	  mL	  
	  3.15	  mL	  	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.8	  mL	  
2.55	  mL	  
Tris	  +	  
Cacodylate	  pH	  
9.0	  50	  mM	  
.5	  mL	  of	  Tris	  +	  
Caco	  pH	  9.0	  	  
.075	  mL	  
Mg(Ac)2	  
.075	  mL	  
Argininamide	  
5.8	  mL	  50%	  
PEG	  1000	  	  
3.55	  mL	  H2O	  
.5	  mL	  	  
.075	  mL	  
.075	  mL	  
6.0	  mL	  
3.35	  mL	  
.5	  mL	  	  
	  .075	  mL	  	  
.075	  mL	  
6.2	  mL	  
3.15	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.4	  mL	  
2.95	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.6	  mL	  
2.75	  mL	  
.5	  mL	  
.075	  mL	  
.075	  mL	  
6.8	  mL	  
2.55	  mL	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20T Fine Mini-Screen 11  
 
Stock solutions: 
50% (w/w) PEG-1000 
1M MgSO4 
1M L-argininamide 
1M sodium cacodylate pH 6.0 
0.5M Tris pH 9.0 
 
	  
(1)  
29% PEG-1000 
5mM argininamide 
5mM MgSO4 
50mM sodium cacodylate 
pH 6.0 
 
5.8 mL PEG-1000 
50 µL argininamide 
50 µL MgSO4 
500 µL sodium 
cacodylate 
3.6 mL H2O 
 
(2) 
29% PEG-1000 
10mM argininamide 
10mM MgSO4 
50mM sodium cacodylate 
pH 6.0 
 
5.8 mL 
100 µL 
100 µL 
500 µL 
 
3.5 mL H2O 
(3) 
29% PEG-1000 
20mM MgSO4 
50mM Tris pH 9.0 
 
5.8 mL 
200 µL 
1 mL 
3 mL H2O 
(4) 
30% PEG-1000 
50mM Tris pH 9.0 
7.5mM argininamide 
7.5mM MgSO4 
 
6.0 mL 
1 mL 
75 µL 
75 µL 
2.85 mL H2O 
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